Automatic injection devices offer an alternative to manually-operated syringes for administering therapeutic agents into patients' bodies and allowing patients to self-administer therapeutic agents. Automatic injection devices may be used to administer medications under emergency conditions, for example, to administer epinephrine to counteract the effects of a severe allergic reaction. Automatic injection devices have also been described for use in administering anti-arrhythmic medications and selective thrombolytic agents during a heart attack. See, for example, U.S. Pat. Nos. 3,910,260; 4,004,577; 4,689,042; 4,755,169; and 4,795,433, the entire contents of which are incorporated herein in their entirety by reference. Various types of automatic injection devices are also described in, for example, U.S. Pat. Nos. 3,941,130; 4,261,358; 5,085,642; 5,092,843; 5,102,393; 5,267,963; 6,149,626; 6,270,479; and 6,371,939; and International Patent Publication No. WO/2008/005315, the entire contents of which are incorporated herein in their entirety by reference.
Conventionally, an automatic injection device houses a syringe and, when operated, causes the syringe to move forwardly and a needle to project from the housing so that a therapeutic agent contained in the syringe is ejected into a patient's body.
Exemplary embodiments provide automatic injection devices, housing components for automatic injection devices and methods for fabricating the same. An exemplary housing of an automatic injection device may be overmolded with one or more gripping surfaces to facilitate gripping and manipulation of the automatic injection device by a user when performing an injection. In an exemplary embodiment, an overmolded left gripping surface may extend along a left side of the housing and an overmolded right gripping surface may extend along a right side of the housing opposite to the left side.
In accordance with an exemplary embodiment, an automatic injection device is provided with a housing enclosing a cavity for accommodating a container. A first overmolded gripping surface is provided to extend longitudinally along a portion of the housing on a first exterior surface of the housing. A second overmolded griping surface is provided to extend longitudinally along a portion of the housing on a second exterior surface of the housing opposite to the first exterior surface.
In an exemplary embodiment, the first and second overmolded gripping surfaces on the housing are formed of a first material having a first touch perception, and non-gripping surfaces on the housing are formed of a second material having a second touch perception. In an exemplary embodiment, the first and second overmolded gripping surfaces on the housing are formed of a first material having a first hardness, and non-gripping surfaces on the housing are formed of a second material having a second higher hardness.
In an exemplary embodiment, the automatic injection device includes a removable distal cap for protectively covering an injection needle couplable to the container, an exterior surface of the distal cap including an overmolded gripping surface for facilitating gripping and removal of the distal cap. In an exemplary embodiment, the automatic injection device includes a firing button protruding from an aperture in the housing and including an overmolded contact surface for facilitating actuation of the firing button by a user. In an exemplary embodiment, the automatic injection device includes a proximal terminal end for covering a proximal end of the automatic injection device, the proximal terminal end having an overmolded exterior surface. In an exemplary embodiment, a top surface of the proximal terminal end includes a recessed surface for directing and facilitating accommodation of a user's hand or finger for gripping the automatic injection device.
In accordance with another exemplary embodiment, a method is provided for assembling an automatic injection device. The method includes providing a housing enclosing a cavity for accommodating a container. The method includes overmolding, on the housing, a first gripping surface extending longitudinally along a portion of the housing on a first exterior surface of the housing. The method also includes overmolding, on the housing, a second gripping surface extending longitudinally along a portion of the housing on a second exterior surface of the housing opposite to the first exterior surface.
In an exemplary embodiment, the first and second gripping surfaces on the housing are formed of a first material having a first touch perception, and non-gripping surfaces on the housing are formed of a second material having a second touch perception. In an exemplary embodiment, the first and second gripping surfaces on the housing are formed of a first material having a first hardness, and non-gripping surfaces on the housing are formed of a second material having a second higher hardness.
In an exemplary embodiment, the method includes overmolding a gripping surface on an exterior surface of a distal cap to facilitate gripping and removal of the distal cap, and coupling the distal cap to a distal end of the housing for protectively covering an injection needle. In an exemplary embodiment, the method includes overmolding a gripping surface on a firing button to facilitate activation of the firing button, and providing the firing button within the cavity so that part of the firing button protrudes from an aperture in the housing.
In an exemplary embodiment, the method includes overmolding a gripping surface on an exterior surface of a proximal terminal end, and coupling the proximal terminal end to a proximal end of the housing. In an exemplary embodiment, a top surface of the proximal terminal end includes a recessed surface for directing a user's hand or finger for gripping the automatic injection device.
In accordance with another exemplary embodiment, an automatic injection device is provided including a housing enclosing a cavity for accommodating a container. The housing includes a first overmolded gripping region, a second overmolded gripping region, and a recessed region abutting the first and second overmolded gripping regions.
In an exemplary embodiment, the recessed region is disposed between the first and second overmolded gripping regions. In an exemplary embodiment, a width of the housing at the recessed region is smaller than a width of the housing at the first overmolded gripping region and a width of the housing at the second overmolded gripping region. In an exemplary embodiment, the recessed region lacks a gripping surface.
In an exemplary embodiment, the first overmolded gripping region is formed by a proximal terminal end of the housing having an exterior surface that is overmolded with a gripping surface. In an exemplary embodiment, the second overmolded gripping region of the housing has a tapered tubular structure.
The foregoing and other objects, aspects, features, and advantages of exemplary embodiments will become more apparent and may be better understood by referring to the following description taken in conjunction with the accompanying drawings, in which:
Exemplary embodiments provide automatic injection devices having housings that are particularly designed and configured for reliable, safe, ergonomic and comfortable handling by users. Exemplary embodiments also provide housing components for automatic injection devices that are particularly designed and configured for reliable, safe, ergonomic and comfortable handling by users. Exemplary embodiments also provide methods for fabricating exemplary housings for automatic injection devices and automatic injection devices including exemplary housings.
In one exemplary embodiment, one or more overmolded gripping surfaces may be provided on an exterior surface of an exemplary automatic injection device housing in order to allow the device to be easily, comfortably and reliably gripped and manipulated by a user. The exemplary overmolded gripping surfaces are particularly configured and positioned on the housing to prevent slippage from the hands of the user, and thereby to avoid injury to the user and others in the vicinity. Furthermore, the exemplary overmolded gripping surfaces are particularly configured and positioned to be ergonomic and comfortable to use, particularly by physically weak users, for example, older users, users who suffer from rheumatoid arthritis, and the like.
In user tests performed using exemplary automatic injection devices, test participants appreciated exemplary overmolded gripping surfaces on the sides of the devices and the relatively large size and ergonomic shape of the device. The test participants provided high ratings for handling and grip of exemplary devices, in which the overmolded gripping surfaces were the primary factor in test participants' high ratings of exemplary device configurations for handling and grip, compared to devices without overmolded gripping surfaces. For several usability factors, there was a significant positive correlation between Cochin scores and exemplary device configurations, which indicates that exemplary devices are well-suited for use by users with hand dysfunction.
An exemplary automatic injections device may contain and may be used to administer a dose of a TNFα inhibitor. In an exemplary embodiment, the TNFα inhibitor may be a human TNFα antibody or antigen-biding portion thereof. In an exemplary embodiment, the human TNFα antibody or antigen-binding portion thereof may be adalimumab (HUMIRA®) or golimumab.
Certain terms are defined in this section to facilitate understanding of exemplary embodiments.
The terms “automatic injection device” and “autoinjector,” as used herein, refer to a device that enables a patient to self-administer a therapeutically effective dose of a therapeutic agent, wherein the device differs from a conventional syringe by the inclusion of a mechanism for automatically delivering the therapeutic agent to the patient by injection when the mechanism is engaged.
The terms “vessel” and “container,” as used herein, refer to a syringe or cartridge that may be used in an exemplary automatic injection device for holding a dose of a therapeutic agent.
The terms “syringe” and “cartridge,” as used herein, refer to a sterile barrel portion of an automatic injection device that is filled with a dose of a therapeutic agent prior to distribution or sale of the device to a patient or other non-medical professional for administration of the therapeutic agent to a patient. In an exemplary embodiment, a distal end of the barrel portion of a syringe may be coupled to a sterile hypodermic injection needle. In an exemplary embodiment, a distal end of the barrel portion of a cartridge may not be coupled to an injection needle. That is, in exemplary embodiments, a syringe may be a cartridge with a pre-attached injection needle coupled to its barrel portion.
Exemplary embodiments described herein with reference to a syringe assembly may also be implemented using a cartridge assembly. Similarly, exemplary embodiments described herein with reference to a cartridge assembly may also be implemented using a syringe assembly.
The term “pre-filled syringe,” as used herein, refers to a syringe that is filled with a therapeutic agent immediately prior to administration of the therapeutic agent to a patient, and a syringe that is filled with a therapeutic agent and stored in this pre-filled form for a period of time before administration of the therapeutic agent to a patient.
The terms “injection needle” and “needle,” as used herein, refer to a needle in an automatic injection device that is inserted into a patient's body to deliver a dose of a therapeutic agent into the patient's body. In an exemplary embodiment, the injection needle may be directly coupled to or may otherwise be in contact with a syringe assembly or a cartridge assembly that holds a dose of the therapeutic agent. In another exemplary embodiment, the injection needle may be indirectly coupled to the syringe or cartridge assembly, for example, via a syringe needle and/or a transfer mechanism that provides fluid communication between the syringe or cartridge assembly and the injection needle.
The term “pre-injection state,” as used herein, refers to a state of an automatic injection device prior to activation of the device, i.e., prior to the start of delivery of a therapeutic agent contained in the device.
The term “injection state,” as used herein, refers to one or more states of an automatic injection device during the delivery of a therapeutic agent contained in the device.
The term “post-injection state,” as used herein, refers to completion of delivery of a therapeutically effective dose of a therapeutic agent contained in the device, or removal of the device from the patient prior to completion of delivery of a therapeutically effective dose of the therapeutic agent.
An automatic injection device provided in accordance with exemplary embodiments may include a “therapeutically effective amount” or a “prophylactically effective amount” of an antibody or antibody portion of the invention. A “therapeutically effective amount,” as used herein, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the antibody, antibody portion, or other TNFα inhibitor may vary according to factors such as the disease state, age, sex, and weight of the patient, and the ability of the antibody, antibody portion, or other TNFα inhibitor to elicit a desired response in the patient. A therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody, antibody portion, or other TNFα inhibitor are outweighed by the therapeutically beneficial effects. A “prophylactically effective amount,” as used herein, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in patients prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
The terms “substance” and “therapeutic agent,” as used herein, refer to any type of drug, biologically active agent, biological substance, chemical substance or biochemical substance that is capable of being administered in a therapeutically effective amount to a patient employing exemplary automatic injection devices. Exemplary therapeutic agents usable in exemplary automatic injection devices may include, but are not limited to, agents in a liquid state. Such agents may include, but are not limited to, adalimumab (HUMIRA®) and proteins that are in a liquid solution, e.g., fusion proteins and enzymes. Examples of proteins in solution include, but are not limited to, Pulmozyme (Dornase alfa), Regranex (Becaplermin), Activase (Alteplase), Aldurazyme (Laronidase), Amevive (Alefacept), Aranesp (Darbepoetin alfa), Becaplermin Concentrate, Betaseron (Interferon beta-1b), BOTOX (Botulinum Toxin Type A), Elitek (Rasburicase), Elspar (Asparaginase), Epogen (Epoetin alfa), Enbrel (Etanercept), Fabrazyme (Agalsidase beta), Infergen (Interferon alfacon-1), Intron A (Interferon alfa-2a), Kineret (Anakinra), MYOBLOC (Botulinum Toxin Type B), Neulasta (Pegfilgrastim), Neumega (Oprelvekin), Neupogen (Filgrastim), Ontak (Denileukin diftitox), PEGASYS (Peginterferon alfa-2a), Proleukin (Aldesleukin), Pulmozyme (Dornase alfa), Rebif (Interferon beta-1a), Regranex (Becaplermin), Retavase (Reteplase), Roferon-A (Interferon alfa-2), TNKase (Tenecteplase), and Xigris (Drotrecogin alfa), Arcalyst (Rilonacept), NPlate (Romiplostim), Mircera (methoxypolyethylene glycol-epoetin beta), Cinryze (C1 esterase inhibitor), Elaprase (idursulfase), Myozyme (alglucosidase alfa), Orencia (abatacept), Naglazyme (galsulfase), Kepivance (palifermin) and Actimmune (interferon gamma-1b).
The term “dose” or “dosage,” as used herein, refers to an amount of a therapeutic agent, such as a TNFα inhibitor, which is administered to a patient preferably using the wearable automatic injection device of the invention. In one embodiment, the dose comprises an effective amount, for example, including, but not limited to, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, and 160 mg, of the TNFα inhibitor adalimumab.
The term “dosing,” as used herein, refers to the administration of a therapeutic agent (e.g., an anti-TNFα antibody) to achieve a therapeutic objective (e.g., treatment of rheumatoid arthritis).
The term “dosing regimen,” as used herein, refers to a treatment schedule for a therapeutic agent, such as a TNFα inhibitor, e.g., a treatment schedule over a prolonged period of time and/or throughout the course of treatment, e.g. administering a first dose of a TNFα inhibitor at week 0 followed by a second dose of a TNFα inhibitor on a biweekly dosing regimen.
The term “treatment,” as used herein, refers to therapeutic treatment, as well as prophylactic or suppressive measures, for the treatment of a disorder, such as a disorder in which TNFα is detrimental, e.g., rheumatoid arthritis.
The term “patient” or “user,” as used herein, refers to any type of animal, human or non-human, that may be administered a therapeutic agent using exemplary automatic injection devices.
The term “proximal” refers to a portion or end or component of an exemplary automatic injection device that is farthest from an injection site on a patient's body when the device is held against the patient for an injection or for mimicking an injection.
The term “distal” refers to a portion or end or component of an exemplary automatic injection device that is closest to an injection site on a patient's body when the device is held against the patient for an injection or for mimicking an injection.
The term “planar” is used herein, in a broad lay sense, to mean exactly planar or approximately planar within some tolerance from the exactly planar.
The term “concave” is used herein, in a broad lay sense, to mean exactly concave or approximately concave within some tolerance from the exactly concave.
The term “convex” is used herein, in a broad lay sense, to mean exactly convex or approximately convex within some tolerance from the exactly convex.
The term “elliptical” is used herein, in a broad lay sense, to mean exactly elliptical or approximately elliptical within some tolerance from the exactly elliptical.
The term “oval” is used herein, in a broad lay sense, to mean exactly oval or approximately oval within some tolerance from the exactly oval.
The term “rectangular” is used herein, in a broad lay sense, to mean exactly rectangular or approximately rectangular within some tolerance from the exactly rectangular.
The term “parallel” is used herein, in a broad lay sense, to mean exactly parallel or approximately parallel within some tolerance from the exactly parallel.
The term “straight” is used herein, in a broad lay sense, to mean exactly straight or approximately straight within some tolerance from the exactly straight.
The term “equal” is used herein, in a broad lay sense, to mean exactly equal or approximately equal within some tolerance.
The term “adjacent” is used herein, in a broad lay sense, to mean immediately adjacent or approximately adjacent within some tolerance.
The term “abut” is used herein, in a broad lay sense, to mean immediately abutting or approximately abutting within some tolerance.
The term “transverse axis” is used herein to refer to an axis that is substantially perpendicular to a longitudinal axis.
Exemplary embodiments are described below with reference to certain illustrative embodiments. While exemplary embodiments are described with respect to using an automatic injection device to provide an injection of a dose of a therapeutic agent, one of ordinary skill in the art will recognize that exemplary embodiments are not limited to the illustrative embodiments and that exemplary automatic injection devices may be used to inject any suitable therapeutic agent into a patient. In addition, components of exemplary automatic injection devices and methods of making and using exemplary automatic injection devices are not limited to the illustrative embodiments described below.
In some exemplary embodiments, an exemplary length of the device 100 may be about 4, 4.5, 4.8, 5, 5.5, 6, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.5, 8, 8.5, 9, 9.5, 10 inches, but is not limited to these exemplary lengths. In some exemplary embodiments, an exemplary width of the device 100 (at its widest location) may be about 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0 inches, but is not limited to these exemplary widths. In some exemplary embodiments, an exemplary thickness of the device 100 (at its thickest location) may be about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.18, 1.19, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0 inches, but is not limited to these exemplary thicknesses. In an exemplary embodiment, the device 100 may have an exemplary length of about 6.69 inches, an exemplary width of about 1.46 inches at the widest portion, and an exemplary thickness of about 1.15 inches at the thickest portion. In another exemplary embodiment, the device 100 may have an exemplary length of about 4.8 inches, an exemplary width of about 0.8 inches at the widest portion, and an exemplary thickness of about 0.6 inches at the thickest portion. The exemplary dimensions of the recited exemplary devices allow the device to be conformably and ergonomically held in the grip of a user's hand. This allows a user to reliably and comfortably grip and manipulate the device in order to perform an injection.
Exemplary automatic injection device 100 may include an outer housing 101 for housing a container, such as a syringe or cartridge. The container may be pre-filled with a dose of a therapeutic agent to be injected into a patient's body. The housing 101 of the device, in its assembled form, may have any suitable size and shape for storing and dispensing the dose of the therapeutic agent. The assembled housing 101 may have a shape that is designed and configured to be conformable to a user's hand and so that the user can comfortably and reliably hold the device 100 during an injection. In an exemplary embodiment, the assembled housing 101 may have an elongated structure so that its length taken along the longitudinal axis L is much greater than its width taken along the first transverse axis H and its thickness taken along a second transverse axis V. An exemplary ratio of the length to the width (at the widest location) of the device may be, but is not limited to, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, all intermediate ratios, and the like. An exemplary ratio of the length to the thickness (at the thickest location) of the device may be, but is not limited to, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, all intermediate ratios, and the like.
The housing 101 of the device 100 may be formed of a plurality of body components that are assembled together. In an exemplary embodiment, the housing 101 may be formed from a first body portion 116 and a second body portion 118 that, when cooperatively engaged to each other along their peripheral edges, enclose and provide a cavity therebetween. The first and second body portions may be cooperatively engaged to each other using any suitable technique including, but not limited to, bonding, gluing, ultrasonic welding, friction fit, snap fit, interference fit, screws, attachment between corresponding protrusions and recesses, and the like. One of ordinary skill in the art will recognize that, in other exemplary embodiments, the cavity of the device may be enclosed in a single body component or in three or more body components when assembled together.
A firing button 120 may extend from a surface of the first body portion 116. The firing button 120, when activated by a user, may cause an injection to be performed by the device 100. In an exemplary embodiment, a recessed or concave portion 126 may be provided on the first body portion 116 abutting the firing button 120 to facilitate activation of the firing button 120. The recessed portion 126 may surround the firing button 120 in an exemplary embodiment to accommodate a user's finger as the user presses on the firing button 120.
A transparent inspection window 128 may be provided in a surface of the first body portion 116 to allow a user to view the contents of the device 100. The transparent inspection window 128 may allow the user to view a therapeutic agent contained in the device 100, for example, to ensure clarity of the agent, and to view an end-of-injection indicator that materializes at the end of a successful injection. An exemplary inspection window 128 may be substantially elongated in shape, for example, an elongated rectangle (with sharp or rounded edges), an elongated elliptical shape, and the like, although other shapes are possible. In the elongated inspection window 128, the length extending along the longitudinal axis L may be substantially greater than the width extending along the first transverse axis H. In exemplary embodiments, a ratio between the length and the width of the inspection window may include, but is not limited to, 1.5:1, 2.0:1, 2.5:1, 3.0:1, 3.5:1, 4.0:1, 4.5:1, 5:1, all intermediate ratios, and the like.
A proximal terminal end 172 of the device housing may be provided to cover the proximal end of the device 100. In an exemplary embodiment, the proximal terminal end 172 may be coupled to the proximal end of the assembled first and second body portions. The proximal terminal end 172 may take any suitable size and shape. In an exemplary embodiment, the proximal terminal end 172 may have a substantially tubular configuration with a substantially oval or elliptical shape. In an exemplary embodiment, at least part of the exterior surface of the proximal terminal end 172 may be overmolded with one or more gripping surfaces 173 to facilitate gripping of the proximal portion of the device. In an exemplary embodiment, the entire exterior surface of the proximal terminal end 172 may be covered by an overmolded gripping surface 173. Corresponding recesses may be provided on the exterior surface of the proximal terminal end 172 to accommodate the gripping surfaces.
A removable distal cap 164 may be coupled to the distal end of the assembled first and second body portions to cover the distal end of the device 100 in order to prevent exposure of the injection needle prior to an injection. The distal cap 164 protects against accidental and/or unwanted contact of a user with the injection needle. The distal cap 164 also protects against damage to and contamination of the injection needle when the device is not in use. The distal cap 164 may take any suitable size and shape. In an exemplary embodiment, the distal cap 164 may have a substantially tubular configuration with a substantially oval or elliptical shape. In an exemplary embodiment, a front surface of the distal cap 164 may have a concave cutout portion 168 for accommodating part of the inspection window 128.
In an exemplary embodiment, the exterior surface of the distal cap 164 may lack overmolded gripping surfaces. In other exemplary embodiments, the exterior surface of the distal cap 164 may be overmolded with one or more gripping surfaces 165 for facilitating gripping and removal of the distal cap 164 from the device. In an exemplary embodiment, the entire exterior surface of the distal cap 164 may be covered by an overmolded gripping surface 165. Corresponding recesses may be provided on the exterior surface of the distal cap 164 to accommodate the gripping surfaces.
In an exemplary embodiment, one or more ridges (that protrude from the exterior surface) and/or one or more grooves or divots (that are depressed into the exterior surface) may be provided at the gripping surfaces 165 on the distal cap 164 to further facilitate gripping and manipulation of the device. The shapes and locations of the ridges and/or grooves may be altered as desired, and any desired number of ridges and/or grooves may be provided. In an exemplary embodiment, the ridges and/or grooves may extend substantially perpendicularly to the longitudinal axis L of the device. In an exemplary embodiment, the gripping surfaces 165 may include textured surfaces to improve the tactile feel and further facilitate firm gripping of the device. In an exemplary embodiment, the distal cap 164 may include one or more protrusions 170a, 170b (shown in
In an exemplary embodiment, the distal cap 164 may frictionally engage a recessed or stepped portion of the housing in order to be retained in position on the housing when the device is not in use. In an exemplary embodiment, the distal cap 164 may include a boss for locking and/or joining the cap to the housing until the user is ready to perform an injection. Any suitable mating mechanism may be used in accordance with the teachings of exemplary embodiments.
When the proximal terminal end 172, the first body portion 116 and the second body portion 118 are assembled together, they form a tapered tubular structure. Side surfaces of the body portions 116, 118 abutting the gripping surfaces 173 on the proximal terminal end 172 may include one or more recessed or concave portions 122, 124. In an exemplary embodiment, two recessed portions 122, 124 may be provided at opposite sides of the device abutting the firing button 120. The recessed portions allow the hand of the user to be accommodated in a comfortable position when pressing the firing button 120.
A portion of the body portions 116, 118 abutting the recessed portions 122, 124 may be overmolded with one or more gripping surfaces 154, 156 to facilitate holding and manipulation of the device. In an exemplary embodiment, two gripping surfaces 154, 156 may be provided at opposite side surfaces of the device. A first gripping surface 154 may abut a first recessed portion 122, and a second gripping surfaces 156 may abut a second recessed portion 124. Corresponding recesses may be provided on the exterior surface of the first body portion 116 to accommodate the gripping surfaces.
In an exemplary housing for an automatic injection device, a first overmolded gripping region, a second overmolded gripping region and a recessed region abutting the first and second overmolded gripping regions may be provided. The first overmolded gripping region, the second overmolded gripping region and the recessed region may cooperatively provide an ergonomic and comfortable gripping area at which a user may grip the automatic injection device in order to perform an injection.
In this exemplary embodiment, the first overmolded gripping region may be formed by the proximal terminal end 172 having an overmolded outer surface or covering. The second overmolded gripping region may be formed part of the assembly of the first body portion 116 and the second body portion 118 having one or more overmolded gripping surfaces (for example, gripping surfaces 154, 156). In an exemplary embodiment, the second overmolded gripping region may have a substantially tapered tubular structure for providing an ergonomic fit with a user's hand. The recessed region abutting the first and second overmolded gripping regions may be formed by a portion of the assembly of the first body portion 116 and the second body portion 118 that is narrower in width than the first overmolded gripping region and the second overmolded gripping region. In an exemplary embodiment, the recessed region may be provided between the first and second overmolded gripping regions. In an exemplary embodiment, the recessed region may lack any overmolded gripping surfaces.
In an exemplary embodiment, the second body portion 118 may include a substantially planar front surface (extending substantially along the L-H plane) and left and right side surfaces (extending substantially along the L-V plane). The front surface of the second body portion 118 may contiguously and integrally transition to left and right side surfaces of the second body portion 118. The edges at which the front surface transitions to the side surfaces may be sharp, or smooth and rounded in order to maintain a streamlined shape of the device and for ergonomic handling of the device. The front and/or side surfaces of the second body portion 118 may be substantially flat or slightly convex so that the assembled housing ergonomically fits within a user's hand. The front surface may be wider at the proximal portion 106 of the device than at the distal portion 104. One of ordinary skill in the art will recognize that other exemplary shapes are possible for the second body portion 118 of the device.
As illustrated in
An exemplary container 160 is preferably slidably positioned in the cavity 102 and is coupled to an injection needle (not shown) at a distal end. The injection needle may be covered by a needle shield 162, for example, a soft needle shield and/or a rigid needle shield. A container advancement mechanism may be provided within the housing to mechanically advance the container 160 within and relative to the housing and to eject the therapeutic agent from the container 160 for performing an injection. The container advancement mechanism may include one or more actuators (e.g., one or more biasing members) that move the container from a sheathed position to a projecting position. When the device is in a pre-injection state, the container 160 may be in a sheathed position, i.e., retracted within the housing. When the device is actuated, the container advancement mechanism may advance the container 160 to a projecting position so that the injection needle projects from a distal end of the housing to allow ejection of the therapeutic agent into a patient's body. The distal end of the housing may include an aperture through which the needle may project.
The cavity 102 within the housing may also accommodate a firing engagement mechanism, for example, the firing button 120. The firing button 120, when actuated by depressing, activates the container advancement mechanism that, in turn, advances the container 160 toward the injection site, drives the injection needle into the injection site and delivers the therapeutic agent into the injection site. In an exemplary embodiment, at least a portion of the exterior surface of the firing button 120 may be overmolded with one or more rubberized gripping surfaces to facilitate pressing of the firing button by a user's finger or hand. In an exemplary embodiment, the entire exterior surface of the firing button may be covered by an overmolded gripping surface. In an exemplary embodiment, the gripping surfaces on the firing button 120 may be colored differently from the non-gripping surfaces to provide a visual affordance to indicate which area of the device should be gripped. For example, the one or more gripping surfaces on the firing button 120 may be green, while all other surfaces on the device may be one or more colors that are not green.
As illustrated in
As illustrated in
One of ordinary skill in the art will recognize that other shapes are possible in exemplary automatic injection device 100.
As illustrated in
In user tests performed using exemplary automatic injection devices, test participants liked the overmolded gripping surfaces on the sides of the device, the ridges on the overmolded gripping surfaces, and the relatively large size and ergonomic shape of the device. Most test participants (58%) strongly preferred the handling and grip of an example automatic injection device of the present invention. Overall, the example device configuration received a high average rating of 8.1 out of 10.0. The overmolded gripping surfaces were the primary factor in the participants' high ratings of the example device for handling and grip. For several usability factors, there was a significant positive correlation between Cochin scores and the example device of the present invention with the overmolded gripping surfaces, which indicates that the example device of the present invention is well-suited for those with hand dysfunction.
One of ordinary skill in the art will recognize that the left and right gripping surfaces may have different sizes, shapes and configurations than the exemplary sizes, shapes and configurations shown in
The overmolded gripping surfaces provided in exemplary embodiments may be formed of any suitable material that provides a first soft and high-friction touch perception to a user, as compared to the portions of the device that lack an overmolded gripping surface which provide a second hard and low-friction touch perception to a user. The difference in the sensory perceptions provides a touch affordance to a user, indicating that the device is to be gripped at regions provided with the overmolded gripping surfaces.
In an exemplary embodiment, the overmolded gripping surfaces may be formed of a first type of material having a soft, high-friction touch perception to a user, while the portions of the device lacking overmolded gripping surfaces may be formed of a second type of material having a harder, lower-friction touch perception to a user. In an exemplary embodiment, the overmolded gripping surfaces may be formed of a first material with a lower hardness, while the non-gripping surfaces may be formed of a second material with a higher hardness.
For example, the non-gripping surfaces may be formed of any rigid thermoplastic material or rigid substrate suitable for use in a medical device application and suitable for providing a hard, low-friction touch perception to the user. Rigid thermoplastics can include materials such as polypropylene (PP), polyethylene (PE), polystyrene (PS), high impact polystyrene (HIPS), polycarbonate (PC), acrynitrile-butadiene-styrene (ABS), poly(ethylene terephthalate) (PET), polyamide (PA), PC/ABS blend and PPO/PS blends.
Exemplary overmolded gripping surfaces may be formed of materials having any suitable material grade and hardness for providing a soft, high-friction touch perception to the user.
Exemplary overmolded gripping surface materials may include, but are not limited to, rubber (for example, having a durometer of 50A in one embodiment), thermoplastic elastomers (TPEs), thermoplastic vulcanizate (TPV), and the like. Exemplary thermoplastic elastomers that may be used to form exemplary overmolded gripping surfaces include, but are not limited to, TPEs from KRAIBURG, the Dynaflex™ TPE from PolyOne, the Versaflex™ TPE from PolyOne, the Versollan™ TPE from PolyOne, the OnFlex™ TPE from Polyone, and the like. Exemplary thermoplastic vulcanizates that may be used to form exemplary overmolded gripping surfaces include, but are not limited to, the Santoprene™ thermoplastic from ExxonMobil and the like.
In an exemplary embodiment, the overmolded gripping surfaces may be colored differently from the non-gripping surfaces to provide a visual affordance to indicate which area of the device should be gripped. For example, the left and right overmolded gripping surfaces may be maroon in color while the non-gripping surfaces on the housing may be grey in color.
As illustrated in
Referring to
In an exemplary embodiment, a connecting side 142 extending between ends 136, 138 may connect the first longitudinal side 134 to the first horizontal side 140. In an exemplary embodiment, the first horizontal side 140 may include a beveled edge extending to the first longitudinal side 134 at an angle to both longitudinal axis L and the first transverse axis H.
In an exemplary embodiment, the first longitudinal side 134 of the left overmolded gripping surface 130 may be substantially longer than the first horizontal side 140. An exemplary ratio of the length of the first longitudinal side 134 to the length of the first horizontal side 140 may include, but is not limited to, about 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, all intermediate ratios, and the like.
A distal end 144 of the first longitudinal side 134 may extend toward and connect with an end 146 of a second horizontal side 148 of the left overmolded gripping surface 130. In an exemplary embodiment, a connecting side 150 extending between the ends 144, 146 may connect the first longitudinal side 134 to the second horizontal side 148. In an exemplary embodiment, the connecting side 150 may have a length greater than that of the connecting side 142. In exemplary embodiments, a ratio of the length of the connecting side 150 to the length of the connecting side 142 may include, but is not limited to, 1.5:1, 1.75:1, 2:1, 2.25:1, 2.5:1, 2.75:1, 3:1, 3.25:1, 3.5:1, 3.75:1, 4:1, all intermediate ratios, and the like, but is not limited to these exemplary ratios. The second horizontal side 148 may extend across the left side surface of the first body portion 116 substantially along the second transverse axis V, ending at the peripheral edge of the first body portion 116.
In an exemplary embodiment, the first longitudinal side 134 may be substantially longer than either the first horizontal side 140 or the second horizontal side 148. An exemplary ratio of the length of the first longitudinal side 134 to the length of either horizontal side may include, but is not limited to, about 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, 5.5:1, 6:1, 6.5:1, 7:1, all intermediate ratios, and the like.
In an exemplary embodiment, the overmolded gripping surfaces may be formed of a first type of material having a soft, high-friction touch perception, while the non-gripping surfaces are formed of a second type of material having a harder, lower-friction touch perception. Exemplary overmolded gripping surfaces 165 may be formed of materials having any suitable material grade and hardness for providing a soft, high-friction touch perception to the user. Exemplary overmolded gripping surface materials may include, but are not limited to, rubber (for example, having a durometer of 50A in one embodiment), thermoplastic elastomers (TPEs), thermoplastic vulcanizate (TPV), and the like. Exemplary thermoplastic elastomers that may be used to form exemplary overmolded gripping surfaces include, but are not limited to, TPEs from KRAIBURG, the Dynaflex™ TPE from PolyOne, the Versaflex™ TPE from PolyOne, the Versollan™ TPE from PolyOne, the OnFlex™ TPE from Polyone, and the like. Exemplary thermoplastic vulcanizates that may be used to form exemplary overmolded gripping surfaces include, but are not limited to, the Santoprene™ thermoplastic from ExxonMobil and the like. In an exemplary embodiment, the overmolded gripping surfaces 165 may be colored differently from the non-gripping surfaces to provide a visual affordance to indicate which area of the device should be gripped. For example, the one or more overmolded gripping surfaces 165 on the distal cap 164 may be maroon in color while the non-gripping surfaces on the housing may be grey in color.
The overmolded gripping surfaces 173 may be formed of any suitable material that provides a first soft and high-friction touch perception to a user, as compared to the portions of the device that lack an overmolded gripping surface which provide a second soft and low-friction touch perception to a user. The difference in the sensory perceptions provides a touch affordance to a user, indicating that the device is to be gripped at regions provided with the overmolded gripping surfaces.
In an exemplary embodiment, the overmolded gripping surfaces 173 may be formed of a first type of material having a soft, high-friction touch perception, while the non-gripping surfaces are formed of a second type of material having a harder, lower-friction touch perception. Exemplary overmolded gripping surfaces 173 may be formed of materials having any suitable material grade and hardness for providing a soft, high-friction touch perception to the user. Exemplary overmolded gripping surface materials may include, but are not limited to, rubber (for example, having a durometer of 50A in one embodiment), thermoplastic elastomers (TPEs), thermoplastic vulcanizate (TPV), and the like. Exemplary thermoplastic elastomers that may be used to form exemplary overmolded gripping surfaces include, but are not limited to, TPEs from KRAIBURG, the Dynaflex™ TPE from PolyOne, the Versaflex™ TPE from PolyOne, the Versollan™ TPE from PolyOne, the OnFlex™ TPE from Polyone, and the like. Exemplary thermoplastic vulcanizates that may be used to form exemplary overmolded gripping surfaces include, but are not limited to, the Santoprene™ thermoplastic from ExxonMobil and the like. In an exemplary embodiment, the overmolded gripping surfaces 173 may be colored differently from the non-gripping surfaces to provide a visual affordance to indicate which area of the device should be gripped. For example, the one or more overmolded gripping surfaces 173 on the proximal terminal end 172 may be maroon in color while the non-gripping surfaces on the housing may be grey in color.
In an exemplary embodiment, one or more ridges (that protrude from the exterior surface) and/or one or more grooves or divots (that are depressed into the exterior surface) may be provided on the exterior surface of the proximal terminal end 172 to further facilitate gripping of the proximal portion of the device. The shapes and locations of the ridges and/or grooves may be altered as desired, and any desired number of ridges and/or grooves may be provided. In an exemplary embodiment, the overmolded gripping surfaces 173 may include textured surfaces to improve the tactile feel and further facilitate firm gripping of the device. In an exemplary embodiment, a wrap-around groove 174 may be provided around the circumference of the proximal terminal end 172 and a concave or recessed surface 176 may be provided at the top of the proximal terminal end 172 in order to orient and guide a user's hand and fingers to the device. For example, the concave or recessed surface 176 may accommodate a finger on the surface 176 while the user is performing an injection using the device.
In some exemplary embodiments, the housing 101, the removable distal cap 164 and/or the proximal terminal end 172 of the device 100 may further include graphics, symbols and/or numbers to facilitate use of the automatic injection device. For example, the distal cap 164 may include a depiction of an arrow on an outer surface pointing towards the distal end of the device to indicate how the device should be held relative to the patient (i.e., with the distal end adjacent to the injection site). One of ordinary skill in the art will recognize that the automatic injection device may have any suitable graphics, symbols and/or numbers to facilitate patient instruction, or the automatic injection device may omit such graphics, symbols and/or numbers.
In step 902, a first body portion of the housing is provided or formed. In step 904, one or more gripping surfaces are overmolded on corresponding recesses on the exterior surface of the first body portion to facilitate gripping and manipulation of the device during an injection.
In step 906, a second body portion of the housing is provided or formed. In step 908, one or more gripping surfaces are overmolded on corresponding recesses on the exterior surface of the second body portion to facilitate gripping and manipulation of the device during an injection.
In step 910, a proximal terminal end of the housing is provided or formed. In step 912, one or more gripping surfaces are overmolded on corresponding recesses on the exterior surface of the proximal terminal end to facilitate gripping and manipulation of the device.
In step 914, a removable distal cap of the housing is provided or formed. In step 916, one or more gripping surfaces are overmolded on corresponding recesses on the exterior surface of the distal cap to facilitate removal of the distal cap before performing an injection.
In step 918, a firing button of the housing is provided or formed. In step 920, one or more gripping surfaces are overmolded on the exterior surface of the firing button to facilitate activation of the firing button to perform an injection.
In step 922, one or more internal components of the automatic injection device may be positioned in a cavity defined between the upper and second body portions. Exemplary device components may include, but are not limited to, a container (e.g., a syringe) pre-filled with a therapeutic agent for injecting into a patient, an injection needle coupled to a distal end of the container, a container advancement mechanism for advancing the container within and relative to the housing toward the injection site and for ejecting the therapeutic agent from the container during an injection, a firing button for activating the container advancement mechanism, and the like.
In step 924, the upper and second body portions may be cooperatively engaged to form a body assembly that encloses and holds the internal components within the cavity. In an exemplary embodiment, the body portions may be coupled at their peripheral edges. Any suitable coupling or joining may be used in step 924 including, but not limited to, bonding, gluing, ultrasonic welding, friction fit, snap fit, interference fit, screws, corresponding protrusions and recesses, and the like.
In step 926, the removable distal cap may be removably coupled at a distal end of the body assembly to cover an injection needle or a needle shield that, in turn, covers the injection needle.
In step 928, the proximal terminal end may be coupled at a proximal end of the body assembly.
Any suitable fabrication technique may be used to form any of the device components including, but not limited to, injection molding. The device components may be formed of any suitable material including, but not limited to, plastics, thermoplastics, polycarbonates, metals, and the like.
It is noted that the order of the steps discussed herein may be altered as desired and that other fabrication steps/techniques are possible and are considered within the spirit and scope of the present invention.
Automatic Injection Device User Tests
Forty-four test participants were recruited to test both the exemplary automatic injection devices having overmolded gripping surfaces of the present invention and four alternate automatic injection devices without such gripping surfaces. A majority of the participants were suffering from rheumatoid arthritis (RA) at the time of the test. The participants were diagnosed with RA from 1 to 40 years ago, with an average age of diagnosis of 9 years ago. Four participants were suffering from Crohn's disease at the time of the test.
Test Procedure
Each test participant tested the different exemplary automatic injection device configurations. In particular, in an example device use phase, each test participant performed a simulated injection (i.e., an injection with clipped needles and no medicament) using the devices. After he/she performed a simulated injection, each test participant was asked a series of follow-up questions designed to assess the participant's approval of the form and function of the devices. These questions included questions on, for example, the size, shape, ease of handling, comfort of holding, overall user experience, and the like.
Device Handling and Gripping
Upon performing simulated injections using the different device configurations, test participants were asked to provide feedback and comparative ratings on handling and grip, overall ease of use, and comfort in performing the injection steps. All device configurations were rated on a scale of 1 (very negative) to 10 (very positive).
Most test participants (58%) strongly preferred the handling and grip of the example device configuration of the present invention, compared to four alternate device configurations that did not include overmolded gripping surfaces. Test participants particularly liked the rubberized overmolded grips on the side of the example device and its relatively large size, which made the example device easy and comfortable to hold. The rubberized overmolded grips were the primary factor in participants' high ratings of the example device configuration for handling and grip as taught herein.
Furthermore, a correlation analysis was performed on hand dysfunction using the Cochin hand disability scale with the ratings provided for certain usability factors: handling and gripping, ease of use, ease of starting and performing an injection, comfort of performing injection, acceptability and overall preference. For several usability factors, there was a significant positive correlation between Cochin scores and the example device configuration of the present invention, which indicates that this example device configuration is well-suited for those with hand dysfunction.
Comfort of Device Holding and Use
Upon performing simulated injections in the example device use phase, test participants were asked to rate the comfort of holding the example device configuration of the present invention and four alternate device configurations that did not include any overmolded gripping surfaces. Test participants rated each device configuration on a scale from 1 (very low confidence) to 7 (very high confidence). Most test participants favored the example device configuration of the present invention for comfort in performing injection steps, with 45% rating it the highest.
Ease of Device Use and Handling
Upon initial exposure to the example device and before receiving instructions or a demonstration on use, test participants were asked about the perceived ease of use of the example device configuration of the present invention and four alternate device configurations that did not include any overmolded gripping surfaces. Test participants rated each device configuration on a scale from 1 (very difficult) to 7 (very easy). All of the device configurations received high ratings for their perceived ease of use.
Upon performing simulated injections in the actual device use phase, test participants were asked to rate the ease of handling each device configuration. Test participants rated each device configuration on a scale from 1 (very low confidence) to 7 (very high confidence). Furthermore, upon performing simulated injections using the device configuration in the third actual device use phase, test participants were also asked to rate the configurations on their overall ease of use on a scale of 1 (very difficult) to 10 (very easy).
Most test participants (42%) found the example device configuration of the present invention easiest to use compared to four alternate device configurations that did not include overmolded gripping surfaces. Overall, the example device configuration of the present invention received a high average rating of 7.97 out of 10.0.
Device Size
Upon performing simulated injections in the example device use phase, test participants were asked to rate the overall size of the example device configuration of the present invention and four alternate device configurations that did not include any overmolded gripping surfaces on a scale of 1 (very low confidence) to 7 (very high confidence). All of the device configurations generally received positive ratings for their overall shape. In general, test participants who struggled to form a tight fist preferred larger devices. The example device configuration of the present invention generally received the highest ratings.
Device Shape
Upon performing simulated injections in the actual device use phase, test participants were asked to rate the overall shape of the example device configuration of the present invention and four alternate device configurations that did not include any overmolded gripping surfaces on a scale of 1 (very low confidence) to 7 (very high confidence).
All of the device configurations generally received positive ratings for their overall size. In general, test participants who struggled to form a tight fist preferred larger devices. With respect to the example device configuration of the present invention, many participants found that the shape fit nicely in their hand.
The contents of all references, including patents and patent applications, cited throughout this application are hereby incorporated herein by reference in their entirety. The appropriate components and methods of those references may be selected for the invention and embodiments thereof. Still further, the components and methods identified in the Background section are integral to this disclosure and can be used in conjunction with or substituted for components and methods described elsewhere in the disclosure within the scope of the invention.
In describing exemplary embodiments, specific terminology is used for the sake of clarity. For purposes of description, each specific term is intended to, at least, include all technical and functional equivalents that operate in a similar manner to accomplish a similar purpose. Additionally, in some instances where a particular exemplary embodiment includes a plurality of system elements or method steps, those elements or steps may be replaced with a single element or step. Likewise, a single element or step may be replaced with a plurality of elements or steps that serve the same purpose. Further, where parameters for various properties are specified herein for exemplary embodiments, those parameters may be adjusted up or down by 1/20th, 1/10th, ⅕th, ⅓rd, ½nd, and the like, or by rounded-off approximations thereof, unless otherwise specified. Moreover, while exemplary embodiments have been shown and described with references to particular embodiments thereof, those of ordinary skill in the art will understand that various substitutions and alterations in form and details may be made therein without departing from the scope of the invention. Further still, other aspects, functions and advantages are also within the scope of the invention.
Exemplary flowcharts are provided herein for illustrative purposes and are non-limiting examples of methods. One of ordinary skill in the art will recognize that exemplary methods may include more or fewer steps than those illustrated in the exemplary flowcharts, and that the steps in the exemplary flowcharts may be performed in a different order than shown.
This application is a continuation of U.S. patent application Ser. No. 13/357,507, filed Jan. 24, 2012 (now U.S. Pat. No. 9,265,887) which is a non-provisional application of and claims priority to U.S. Provisional Patent Application No. 61/435,465, filed Jan. 24, 2011, the entire contents of both applications being expressly incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
2219089 | Everett | Oct 1940 | A |
2398544 | Lockhart | Apr 1946 | A |
2459875 | Folkman | Jan 1949 | A |
2565081 | Maynes | Aug 1951 | A |
2591457 | Maynes | Apr 1952 | A |
2701566 | Krug | Feb 1955 | A |
2752918 | Uytenbogaart | Jul 1956 | A |
2832339 | Sarnoff et al. | Apr 1958 | A |
2888924 | Dunmire | Jun 1959 | A |
2960087 | Uytenbogaart | Nov 1960 | A |
3051173 | Johnson et al. | Aug 1962 | A |
3055362 | Uytenbogaart | Sep 1962 | A |
3066670 | Stauffer | Dec 1962 | A |
3136313 | Enstrom et al. | Jun 1964 | A |
3314428 | Johnson et al. | Apr 1967 | A |
3330279 | Sarnoff et al. | Jul 1967 | A |
3403680 | Sinclair et al. | Oct 1968 | A |
3496937 | Fletcher | Feb 1970 | A |
3541663 | Szpur | Nov 1970 | A |
3543603 | Gley | Dec 1970 | A |
3605743 | Arce | Sep 1971 | A |
3618603 | Levenson | Nov 1971 | A |
3656472 | Ben Moura | Apr 1972 | A |
3702609 | Steiner | Nov 1972 | A |
3712301 | Sarnoff | Jan 1973 | A |
3742948 | Post et al. | Jul 1973 | A |
3797488 | Hurschman et al. | Mar 1974 | A |
3797489 | Sarnoff | Mar 1974 | A |
3882863 | Sarnoff et al. | May 1975 | A |
3892237 | Steiner | Jul 1975 | A |
3910260 | Sarnoff et al. | Oct 1975 | A |
3941130 | Tibbs | Mar 1976 | A |
4004577 | Sarnoff | Jan 1977 | A |
4031893 | Kaplan et al. | Jun 1977 | A |
4106770 | Gray | Aug 1978 | A |
4178928 | Tischlinger | Dec 1979 | A |
4202314 | Smirnov et al. | May 1980 | A |
4214584 | Smirnov et al. | Jul 1980 | A |
4226235 | Sarnoff et al. | Oct 1980 | A |
4258713 | Wardlaw | Mar 1981 | A |
4261358 | Vargas et al. | Apr 1981 | A |
4275729 | Silver et al. | Jun 1981 | A |
4356828 | Jamshidi | Nov 1982 | A |
4394863 | Bartner | Jul 1983 | A |
4399216 | Axel et al. | Aug 1983 | A |
4425120 | Sampson et al. | Jan 1984 | A |
4437859 | Whitehouse et al. | Mar 1984 | A |
4447231 | Bekkering | May 1984 | A |
4510245 | Cousens et al. | Apr 1985 | A |
4530695 | Phillips et al. | Jul 1985 | A |
4565543 | Bekkering et al. | Jan 1986 | A |
4573976 | Sampson et al. | Mar 1986 | A |
4578064 | Sarnoff et al. | Mar 1986 | A |
4610254 | Morgan et al. | Sep 1986 | A |
4619265 | Morgan et al. | Oct 1986 | A |
4624660 | Mijers et al. | Nov 1986 | A |
4634665 | Axel et al. | Jan 1987 | A |
4637403 | Garcia et al. | Jan 1987 | A |
4640686 | Dalling et al. | Feb 1987 | A |
4664653 | Sagstetter et al. | May 1987 | A |
4678461 | Mesa | Jul 1987 | A |
4689042 | Sarnoff et al. | Aug 1987 | A |
4723937 | Sarnoff et al. | Feb 1988 | A |
4755169 | Sarnoff et al. | Jul 1988 | A |
4795432 | Karczmer | Jan 1989 | A |
4795433 | Sarnoff | Jan 1989 | A |
4816397 | Boss et al. | Mar 1989 | A |
4816567 | Cabilly et al. | Mar 1989 | A |
4820286 | van der Wal | Apr 1989 | A |
4822340 | Kamstra | Apr 1989 | A |
4850994 | Zerbst et al. | Jul 1989 | A |
4852768 | Bartsch | Aug 1989 | A |
4902279 | Schmidtz et al. | Feb 1990 | A |
4923447 | Morgan | May 1990 | A |
4927416 | Tomkiel | May 1990 | A |
4929237 | Medway | May 1990 | A |
4955868 | Klein | Sep 1990 | A |
4966592 | Burns et al. | Oct 1990 | A |
4968615 | Koszinowski et al. | Nov 1990 | A |
4994034 | Botich et al. | Feb 1991 | A |
5041088 | Ritson et al. | Aug 1991 | A |
5042977 | Bechtold et al. | Aug 1991 | A |
5049133 | Villen Pascual | Sep 1991 | A |
D322479 | Miyaguchi | Dec 1991 | S |
5071353 | van der Wal | Dec 1991 | A |
5085641 | Sarnoff et al. | Feb 1992 | A |
5085642 | Sarnoff et al. | Feb 1992 | A |
5092842 | Bechtold et al. | Mar 1992 | A |
5092843 | Monroe et al. | Mar 1992 | A |
5102393 | Sarnoff et al. | Apr 1992 | A |
5104380 | Holman et al. | Apr 1992 | A |
5114406 | Gabriel et al. | May 1992 | A |
5114410 | Caralt Batlle | May 1992 | A |
5137516 | Rand et al. | Aug 1992 | A |
5163918 | Righi et al. | Nov 1992 | A |
5168062 | Stinski | Dec 1992 | A |
5179017 | Axel et al. | Jan 1993 | A |
5201708 | Martin | Apr 1993 | A |
5223409 | Ladner et al. | Jun 1993 | A |
5224936 | Gallagher | Jul 1993 | A |
5225539 | Winter | Jul 1993 | A |
5231024 | Moeller et al. | Jul 1993 | A |
5242240 | Gorham | Sep 1993 | A |
5244465 | Michel | Sep 1993 | A |
5259840 | Boris | Nov 1993 | A |
5263934 | Haak | Nov 1993 | A |
5267963 | Bachynsky | Dec 1993 | A |
5267972 | Anderson | Dec 1993 | A |
5267976 | Guerineau et al. | Dec 1993 | A |
5273544 | van der Wal | Dec 1993 | A |
D343897 | Rand et al. | Feb 1994 | S |
5295965 | Wilmot | Mar 1994 | A |
5295975 | Lockwood, Jr. | Mar 1994 | A |
5298024 | Richmond | Mar 1994 | A |
D346219 | Fardigh | Apr 1994 | S |
5300030 | Crossman et al. | Apr 1994 | A |
5318538 | Martin | Jun 1994 | A |
5320609 | Haber et al. | Jun 1994 | A |
5334144 | Alchas et al. | Aug 1994 | A |
5342308 | Boschetti | Aug 1994 | A |
5346480 | Hess et al. | Sep 1994 | A |
5358489 | Wyrick | Oct 1994 | A |
5376080 | Petrussa | Dec 1994 | A |
5378233 | Haber et al. | Jan 1995 | A |
5383864 | van den Heuvel | Jan 1995 | A |
5383865 | Michel | Jan 1995 | A |
5391151 | Wilmot | Feb 1995 | A |
5425715 | Dalling et al. | Jun 1995 | A |
5433712 | Stiles et al. | Jul 1995 | A |
5478316 | Bitdinger et al. | Dec 1995 | A |
5480387 | Gabriel et al. | Jan 1996 | A |
5530101 | Queen et al. | Jun 1996 | A |
5531705 | Alter et al. | Jul 1996 | A |
5567160 | Massino | Oct 1996 | A |
5569192 | van der Wal | Oct 1996 | A |
5585089 | Queen et al. | Dec 1996 | A |
5591138 | Vaillancourt | Jan 1997 | A |
5599309 | Marshall et al. | Feb 1997 | A |
5599314 | Neill | Feb 1997 | A |
5616128 | Meyer | Apr 1997 | A |
5620421 | Schmitz | Apr 1997 | A |
5634906 | Haber et al. | Jun 1997 | A |
5637094 | Stewart, Jr. et al. | Jun 1997 | A |
5645534 | Chanoch | Jul 1997 | A |
5645571 | Olson et al. | Jul 1997 | A |
5656272 | Le et al. | Aug 1997 | A |
5658259 | Pearson et al. | Aug 1997 | A |
5681291 | Galli | Oct 1997 | A |
5693761 | Queen et al. | Dec 1997 | A |
5693762 | Queen et al. | Dec 1997 | A |
5744360 | Hu et al. | Apr 1998 | A |
5779677 | Frezza | Jul 1998 | A |
5792190 | Olson et al. | Aug 1998 | A |
5797969 | Olson et al. | Aug 1998 | A |
5807335 | Kriesel et al. | Sep 1998 | A |
5807346 | Frezza | Sep 1998 | A |
5817111 | Riza | Oct 1998 | A |
5843036 | Olive et al. | Dec 1998 | A |
5845644 | Hughes et al. | Dec 1998 | A |
5860957 | Jacobsen et al. | Jan 1999 | A |
5885250 | Kriesel et al. | Mar 1999 | A |
5919212 | Olson et al. | Jul 1999 | A |
5931817 | Nguyen et al. | Aug 1999 | A |
5957886 | Weston | Sep 1999 | A |
5957897 | Jeffrey | Sep 1999 | A |
5984900 | Mikkelsen | Nov 1999 | A |
5993421 | Kriesel | Nov 1999 | A |
6048336 | Gabriel | Apr 2000 | A |
6056728 | von Schuckmann | May 2000 | A |
6077247 | Marshall et al. | Jun 2000 | A |
D428651 | Andersson et al. | Jul 2000 | S |
6090070 | Hager et al. | Jul 2000 | A |
6090080 | Jost et al. | Jul 2000 | A |
6090382 | Salfeld et al. | Jul 2000 | A |
6099503 | Stradella | Aug 2000 | A |
6102896 | Roser | Aug 2000 | A |
6110147 | Perouse | Aug 2000 | A |
6125299 | Groenke et al. | Sep 2000 | A |
6149626 | Bachynsky et al. | Nov 2000 | A |
6159181 | Crossman et al. | Dec 2000 | A |
6171285 | Johnson | Jan 2001 | B1 |
6203530 | Stewart, Sr. | Mar 2001 | B1 |
6210369 | Wilmot et al. | Apr 2001 | B1 |
6213987 | Hirsch et al. | Apr 2001 | B1 |
6221044 | Greco | Apr 2001 | B1 |
6241709 | Bechtold et al. | Jun 2001 | B1 |
6258068 | Kirchhofer et al. | Jul 2001 | B1 |
6258562 | Salfeld et al. | Jul 2001 | B1 |
6270479 | Bergens et al. | Aug 2001 | B1 |
6277097 | Mikkelsen et al. | Aug 2001 | B1 |
6277098 | Klitmose et al. | Aug 2001 | B1 |
6277099 | Strowe et al. | Aug 2001 | B1 |
6280421 | Kirchhofer et al. | Aug 2001 | B1 |
6312412 | Saied et al. | Nov 2001 | B1 |
6319011 | Motti et al. | Nov 2001 | B1 |
6319233 | Jansen et al. | Nov 2001 | B1 |
6319234 | Restelli et al. | Nov 2001 | B1 |
6322540 | Grabis et al. | Nov 2001 | B1 |
6325066 | Hughes et al. | Dec 2001 | B1 |
6328699 | Eigler et al. | Dec 2001 | B1 |
6334070 | Nova et al. | Dec 2001 | B1 |
D453569 | Himbert | Feb 2002 | S |
6371939 | Bergens et al. | Apr 2002 | B2 |
6387074 | Horppu et al. | May 2002 | B1 |
6387078 | Gillespie, III | May 2002 | B1 |
6413237 | Caizza et al. | Jul 2002 | B1 |
6419658 | Restelli et al. | Jul 2002 | B1 |
D461555 | Binet et al. | Aug 2002 | S |
6448380 | Rathjen et al. | Sep 2002 | B2 |
6451983 | Rathjen et al. | Sep 2002 | B2 |
6454746 | Bydlon et al. | Sep 2002 | B1 |
6475194 | Domici, Jr. et al. | Nov 2002 | B2 |
6498237 | Rathjen et al. | Dec 2002 | B2 |
6502699 | Watson | Jan 2003 | B1 |
6509015 | Salfeld et al. | Jan 2003 | B1 |
6517517 | Farrugia et al. | Feb 2003 | B1 |
6544234 | Gabriel | Apr 2003 | B1 |
6575939 | Brunel | Jun 2003 | B1 |
6589210 | Rolfe | Jul 2003 | B1 |
6593458 | Rathjen et al. | Jul 2003 | B1 |
6656163 | Marshall et al. | Dec 2003 | B1 |
6656164 | Smith | Dec 2003 | B1 |
6673035 | Rice et al. | Jan 2004 | B1 |
6692469 | Weekes et al. | Feb 2004 | B1 |
6697671 | Nova et al. | Feb 2004 | B1 |
6712788 | Righi et al. | Mar 2004 | B2 |
6743203 | Pickhard | Jun 2004 | B1 |
6752798 | McWethy et al. | Jun 2004 | B2 |
6767336 | Kaplan | Jul 2004 | B1 |
D494270 | Reschke | Aug 2004 | S |
6773415 | Heiniger | Aug 2004 | B2 |
6796967 | Jensen | Sep 2004 | B2 |
6802827 | Andersson | Oct 2004 | B2 |
6805686 | Fathallah et al. | Oct 2004 | B1 |
6808507 | Roser | Oct 2004 | B2 |
6817989 | Svendsen et al. | Nov 2004 | B2 |
6872080 | Pastrick et al. | Mar 2005 | B2 |
6872194 | Doyle et al. | Mar 2005 | B2 |
6926697 | Malenchek | Aug 2005 | B2 |
6932793 | Marshall et al. | Aug 2005 | B1 |
6945960 | Barker et al. | Sep 2005 | B2 |
6969259 | Pastrick et al. | Nov 2005 | B2 |
6970742 | Mann et al. | Nov 2005 | B2 |
6976976 | Doyle | Dec 2005 | B2 |
6986760 | Giambattista et al. | Jan 2006 | B2 |
7004929 | McWethy et al. | Feb 2006 | B2 |
D518175 | Hardin, Jr. et al. | Mar 2006 | S |
7056306 | Halseth et al. | Jun 2006 | B1 |
7115095 | Eigler et al. | Oct 2006 | B2 |
7137953 | Eigler et al. | Nov 2006 | B2 |
7223394 | Salfeld et al. | May 2007 | B2 |
D545439 | Draudt et al. | Jun 2007 | S |
7320682 | Cocker et al. | Jan 2008 | B2 |
7361160 | Hommann et al. | Apr 2008 | B2 |
7416540 | Edwards et al. | Aug 2008 | B2 |
7483743 | Mann et al. | Jan 2009 | B2 |
7497847 | Crawford et al. | Mar 2009 | B2 |
7517334 | Jacobs et al. | Apr 2009 | B2 |
7541031 | Salfeld et al. | Jun 2009 | B2 |
7588761 | Salfeld et al. | Sep 2009 | B2 |
7590449 | Mann et al. | Sep 2009 | B2 |
7648482 | Edwards et al. | Jan 2010 | B2 |
7648483 | Edwards et al. | Jan 2010 | B2 |
7682155 | Raven et al. | Mar 2010 | B2 |
7694828 | Swift et al. | Apr 2010 | B2 |
7717854 | Mann et al. | May 2010 | B2 |
7731686 | Edwards et al. | Jun 2010 | B2 |
7731690 | Edwards et al. | Jun 2010 | B2 |
7736333 | Gillespie, III | Jun 2010 | B2 |
7744561 | Stamp | Jun 2010 | B2 |
D619702 | Galbraith | Jul 2010 | S |
7749194 | Edwards et al. | Jul 2010 | B2 |
D621932 | Sonleiter et al. | Aug 2010 | S |
D622374 | Julian et al. | Aug 2010 | S |
7771397 | Olson | Aug 2010 | B1 |
D628690 | Galbraith | Dec 2010 | S |
D629098 | Sonleiter et al. | Dec 2010 | S |
D629509 | Julian et al. | Dec 2010 | S |
7863426 | Wan et al. | Jan 2011 | B2 |
D633199 | MacKay et al. | Feb 2011 | S |
7918823 | Edwards et al. | Apr 2011 | B2 |
7919264 | Maksymowych et al. | Apr 2011 | B2 |
D638935 | Gilmore, III et al. | May 2011 | S |
7938802 | Bicknell et al. | May 2011 | B2 |
7947017 | Edwards et al. | May 2011 | B2 |
D641077 | Sanders et al. | Jul 2011 | S |
D645139 | Sawhney et al. | Sep 2011 | S |
8016788 | Edwards et al. | Sep 2011 | B2 |
8021344 | Edwards et al. | Sep 2011 | B2 |
D647613 | Paget et al. | Oct 2011 | S |
8034906 | Borhani et al. | Oct 2011 | B2 |
8069097 | Patrick et al. | Nov 2011 | B2 |
D650070 | Mori | Dec 2011 | S |
D653329 | Lee-Sepsick | Jan 2012 | S |
8105281 | Edwards et al. | Jan 2012 | B2 |
8123719 | Edwards et al. | Feb 2012 | B2 |
8162887 | Bicknell et al. | Apr 2012 | B2 |
8172082 | Edwards et al. | May 2012 | B2 |
8187836 | Hsieh | May 2012 | B2 |
8206360 | Edwards et al. | Jun 2012 | B2 |
8216583 | Kruase et al. | Jul 2012 | B2 |
8226610 | Edwards et al. | Jul 2012 | B2 |
8231573 | Edwards et al. | Jul 2012 | B2 |
8313466 | Edwards et al. | Nov 2012 | B2 |
8361026 | Edwards et al. | Jan 2013 | B2 |
8372030 | Dixon et al. | Feb 2013 | B2 |
8372400 | Salfeld et al. | Feb 2013 | B2 |
D677380 | Julian et al. | Mar 2013 | S |
8425462 | Edwards et al. | Apr 2013 | B2 |
9086418 | Maksymowych et al. | Jul 2015 | B2 |
9180244 | Anderson et al. | Nov 2015 | B2 |
20010005781 | Bergens et al. | Jun 2001 | A1 |
20010025168 | Gross et al. | Sep 2001 | A1 |
20010053894 | Steenfeldt-Jensen et al. | Dec 2001 | A1 |
20020002344 | Douglas et al. | Jan 2002 | A1 |
20020016563 | Hill et al. | Feb 2002 | A1 |
20020042592 | Wilmot et al. | Apr 2002 | A1 |
20020095120 | Larsen et al. | Jul 2002 | A1 |
20020111587 | Hommann et al. | Aug 2002 | A1 |
20020161337 | Shaw et al. | Oct 2002 | A1 |
20020169408 | Beretta et al. | Nov 2002 | A1 |
20020183690 | Arnisolle | Dec 2002 | A1 |
20030004466 | Bitdinger et al. | Jan 2003 | A1 |
20030004467 | Musick et al. | Jan 2003 | A1 |
20030012786 | Teoh et al. | Jan 2003 | A1 |
20030023203 | Lavi et al. | Jan 2003 | A1 |
20030023205 | Botich et al. | Jan 2003 | A1 |
20030050606 | Brand et al. | Mar 2003 | A1 |
20030055345 | Eigler et al. | Mar 2003 | A1 |
20030092059 | Salfeld et al. | May 2003 | A1 |
20030093036 | Crossman et al. | May 2003 | A1 |
20030099358 | Michael et al. | May 2003 | A1 |
20030105430 | Lavi et al. | Jun 2003 | A1 |
20030153868 | Azizi et al. | Aug 2003 | A1 |
20030161744 | Vilks et al. | Aug 2003 | A1 |
20030161828 | Abdelghany et al. | Aug 2003 | A1 |
20030187401 | Doyle | Oct 2003 | A1 |
20030206898 | Fischkoff et al. | Nov 2003 | A1 |
20030212362 | Roser | Nov 2003 | A1 |
20030216785 | Edwards et al. | Nov 2003 | A1 |
20030219438 | Salfeld et al. | Nov 2003 | A1 |
20030229308 | Tsals et al. | Dec 2003 | A1 |
20030235585 | Fischkoff et al. | Dec 2003 | A1 |
20030236502 | De La Serna et al. | Dec 2003 | A1 |
20040009172 | Fischkoff et al. | Jan 2004 | A1 |
20040019326 | Gilbert et al. | Jan 2004 | A1 |
20040024367 | Gilbert | Feb 2004 | A1 |
20040025272 | Stvartak et al. | Feb 2004 | A1 |
20040033228 | Krause et al. | Feb 2004 | A1 |
20040039336 | Amark et al. | Feb 2004 | A1 |
20040039337 | Letzing | Feb 2004 | A1 |
20040054319 | Langley et al. | Mar 2004 | A1 |
20040054327 | Gillespie | Mar 2004 | A1 |
20040126372 | Banerjee et al. | Jul 2004 | A1 |
20040126373 | Banerjee et al. | Jul 2004 | A1 |
20040131614 | Banerjee et al. | Jul 2004 | A1 |
20040136989 | Banerjee et al. | Jul 2004 | A1 |
20040136990 | Banerjee et al. | Jul 2004 | A1 |
20040136991 | Banerjee et al. | Jul 2004 | A1 |
20040143298 | Nova et al. | Jul 2004 | A1 |
20040147875 | Wallace et al. | Jul 2004 | A1 |
20040151722 | Banerjee et al. | Aug 2004 | A1 |
20040154133 | Polzin et al. | Aug 2004 | A1 |
20040166111 | Kaymakcalan et al. | Aug 2004 | A1 |
20040199117 | Giambattista et al. | Oct 2004 | A1 |
20040215151 | Marshall et al. | Oct 2004 | A1 |
20040219142 | Banerjee et al. | Nov 2004 | A1 |
20040225262 | Fathallah et al. | Nov 2004 | A1 |
20040229854 | Haan De | Nov 2004 | A1 |
20040249339 | Willis et al. | Dec 2004 | A1 |
20050020979 | Westbye et al. | Jan 2005 | A1 |
20050020984 | Lesch | Jan 2005 | A1 |
20050027255 | Lavi et al. | Feb 2005 | A1 |
20050049550 | Kirchhofer et al. | Mar 2005 | A1 |
20050049561 | Hommann et al. | Mar 2005 | A1 |
20050085776 | Hommann et al. | Apr 2005 | A1 |
20050090647 | Gatanaga et al. | Apr 2005 | A1 |
20050095208 | Battaglia et al. | May 2005 | A1 |
20050096597 | Crawford et al. | May 2005 | A1 |
20050101919 | Brunnberg | May 2005 | A1 |
20050115508 | Little | Jun 2005 | A1 |
20050124940 | Martin et al. | Jun 2005 | A1 |
20050137196 | Timmer et al. | Jun 2005 | A1 |
20050137534 | Hommann | Jun 2005 | A1 |
20050137571 | Hommann | Jun 2005 | A1 |
20050165360 | Stamp | Jul 2005 | A1 |
20050165361 | Marshall et al. | Jul 2005 | A1 |
20050165362 | Slawson | Jul 2005 | A1 |
20050165363 | Judson et al. | Jul 2005 | A1 |
20050171476 | Judson et al. | Aug 2005 | A1 |
20050171477 | Rubin | Aug 2005 | A1 |
20050209569 | Ishikawa et al. | Sep 2005 | A1 |
20050222539 | Gonzales et al. | Oct 2005 | A1 |
20050222540 | Kirchhofer et al. | Oct 2005 | A1 |
20050261634 | Karlsson | Nov 2005 | A1 |
20050261742 | Nova et al. | Nov 2005 | A1 |
20050273054 | Asch | Dec 2005 | A1 |
20050273055 | Harrison et al. | Dec 2005 | A1 |
20050273061 | Hommann et al. | Dec 2005 | A1 |
20050277885 | Scherer | Dec 2005 | A1 |
20050277886 | Hommann et al. | Dec 2005 | A1 |
20050277893 | Liversidge | Dec 2005 | A1 |
20050288633 | Jeffrey | Dec 2005 | A1 |
20060009385 | Hoffman et al. | Jan 2006 | A1 |
20060009810 | Mann et al. | Jan 2006 | A1 |
20060024293 | Salfeld et al. | Feb 2006 | A1 |
20060030819 | Young et al. | Feb 2006 | A1 |
20060036216 | Rimlinger et al. | Feb 2006 | A1 |
20060037158 | Foley et al. | Feb 2006 | A1 |
20060047250 | Hickingbotham et al. | Mar 2006 | A1 |
20060058848 | Piraino et al. | Mar 2006 | A1 |
20060069350 | Buenger et al. | Mar 2006 | A1 |
20060069354 | Buenger et al. | Mar 2006 | A1 |
20060074519 | Barker et al. | Apr 2006 | A1 |
20060083741 | Hoffman et al. | Apr 2006 | A1 |
20060089540 | Meissner | Apr 2006 | A1 |
20060100588 | Brunnberg et al. | May 2006 | A1 |
20060111666 | Hommann et al. | May 2006 | A1 |
20060111674 | Vedrine | May 2006 | A1 |
20060129089 | Stamp | Jun 2006 | A1 |
20060129122 | Wyrick | Jun 2006 | A1 |
20060140907 | Blumberg et al. | Jun 2006 | A1 |
20060167413 | Marshall et al. | Jul 2006 | A1 |
20060178865 | Edwards et al. | Aug 2006 | A1 |
20060189933 | Alheidt et al. | Aug 2006 | A1 |
20060204939 | Bardsley et al. | Sep 2006 | A1 |
20060253083 | Liu | Nov 2006 | A1 |
20070032831 | Eigler et al. | Feb 2007 | A1 |
20070041905 | Hoffman et al. | Feb 2007 | A1 |
20070049865 | Radmer et al. | Mar 2007 | A1 |
20070071747 | Hoffman et al. | Mar 2007 | A1 |
20070081996 | Hoffman et al. | Apr 2007 | A1 |
20070088223 | Mann et al. | Apr 2007 | A1 |
20070129674 | Liversidge | Jun 2007 | A1 |
20070129686 | Daily et al. | Jun 2007 | A1 |
20070129708 | Edwards et al. | Jun 2007 | A1 |
20070142776 | Kovelman et al. | Jun 2007 | A9 |
20070161960 | Chen et al. | Jul 2007 | A1 |
20070172897 | Maksymowych et al. | Jul 2007 | A1 |
20070173772 | Liversidge | Jul 2007 | A1 |
20070197976 | Jacobs et al. | Aug 2007 | A1 |
20070202104 | Banerjee et al. | Aug 2007 | A1 |
20070239117 | Chelak et al. | Oct 2007 | A1 |
20070249813 | Salfeld et al. | Oct 2007 | A1 |
20070292442 | Wan et al. | Dec 2007 | A1 |
20080019969 | Gorman | Jan 2008 | A1 |
20080059133 | Edwards et al. | Mar 2008 | A1 |
20080097337 | Judd et al. | Apr 2008 | A1 |
20080103490 | Edwards et al. | May 2008 | A1 |
20080118496 | Medich et al. | May 2008 | A1 |
20080131374 | Medich et al. | Jun 2008 | A1 |
20080166348 | Kupper et al. | Jul 2008 | A1 |
20080193466 | Banerjee et al. | Aug 2008 | A1 |
20080195052 | Hjertman et al. | Aug 2008 | A1 |
20080195056 | Bishop et al. | Aug 2008 | A1 |
20080208125 | Bicknell et al. | Aug 2008 | A1 |
20080208140 | Barrelle | Aug 2008 | A1 |
20080227136 | Pla et al. | Sep 2008 | A1 |
20080269689 | Edwards et al. | Oct 2008 | A1 |
20080269692 | James et al. | Oct 2008 | A1 |
20080300549 | Verespej et al. | Dec 2008 | A1 |
20080311043 | Hoffman et al. | Dec 2008 | A1 |
20090017472 | Stuhlmuller et al. | Jan 2009 | A1 |
20090024076 | Babaev | Jan 2009 | A1 |
20090024093 | Carrel et al. | Jan 2009 | A1 |
20090024112 | Edwards et al. | Jan 2009 | A1 |
20090028794 | Medich et al. | Jan 2009 | A1 |
20090036870 | Mounce et al. | Feb 2009 | A1 |
20090093792 | Gross et al. | Apr 2009 | A1 |
20090110679 | Li et al. | Apr 2009 | A1 |
20090123378 | Wong et al. | May 2009 | A1 |
20090148513 | Fraunhofer et al. | Jun 2009 | A1 |
20090155205 | Salfeld et al. | Jun 2009 | A1 |
20090157012 | Magne | Jun 2009 | A1 |
20090182284 | Morgan | Jul 2009 | A1 |
20090226530 | Lassner et al. | Sep 2009 | A1 |
20090234298 | Habeshaw et al. | Sep 2009 | A1 |
20090240195 | Schrul et al. | Sep 2009 | A1 |
20090240210 | Walton et al. | Sep 2009 | A1 |
20090258018 | Medich et al. | Oct 2009 | A1 |
20090271164 | Peng et al. | Oct 2009 | A1 |
20090280065 | Willian et al. | Nov 2009 | A1 |
20090291062 | Fraunhofer et al. | Nov 2009 | A1 |
20090299328 | Mudd et al. | Dec 2009 | A1 |
20090304682 | Hoffman et al. | Dec 2009 | A1 |
20090317399 | Pollack et al. | Dec 2009 | A1 |
20100003243 | Okun et al. | Jan 2010 | A1 |
20100016557 | Salfeld et al. | Jan 2010 | A1 |
20100021451 | Wong | Jan 2010 | A1 |
20100022963 | Edwards et al. | Jan 2010 | A1 |
20100040630 | Elden et al. | Feb 2010 | A1 |
20100069845 | Marshall et al. | Mar 2010 | A1 |
20100121276 | Edwards et al. | May 2010 | A1 |
20100160869 | Liversidge | Jun 2010 | A1 |
20100160894 | Julian et al. | Jun 2010 | A1 |
20100211005 | Edwards et al. | Aug 2010 | A1 |
20100241075 | Edwards et al. | Sep 2010 | A1 |
20100278822 | Fraunhofer et al. | Nov 2010 | A1 |
20100309012 | Edwards et al. | Dec 2010 | A1 |
20100318035 | Edwards et al. | Dec 2010 | A1 |
20110002935 | Wan et al. | Jan 2011 | A1 |
20110054414 | Shang et al. | Mar 2011 | A1 |
20110146015 | Moskovich et al. | Jun 2011 | A1 |
20110171227 | Okun et al. | Jul 2011 | A1 |
20110178469 | Johnston et al. | Jul 2011 | A1 |
20110178500 | Shang et al. | Jul 2011 | A1 |
20110218502 | Iio | Sep 2011 | A1 |
20110257602 | Watanabe et al. | Oct 2011 | A1 |
20110300151 | Okun et al. | Dec 2011 | A1 |
20110319822 | Edwards et al. | Dec 2011 | A1 |
20120008811 | Edwards et al. | Jan 2012 | A1 |
20120014956 | Kupper et al. | Jan 2012 | A1 |
20120015335 | Smith et al. | Jan 2012 | A1 |
20120071829 | Edwards et al. | Mar 2012 | A1 |
20120107783 | Julian et al. | May 2012 | A1 |
20120116318 | Edwards et al. | May 2012 | A1 |
20120191047 | Raday et al. | Jul 2012 | A1 |
20120197209 | Bicknell et al. | Aug 2012 | A1 |
20120233834 | Szechinski et al. | Sep 2012 | A1 |
20120238961 | Julian et al. | Sep 2012 | A1 |
20120255136 | Jimenez et al. | Oct 2012 | A1 |
20120289905 | Julian et al. | Nov 2012 | A1 |
Number | Date | Country |
---|---|---|
2741354 | Apr 2010 | CA |
2019296 | Nov 1971 | DE |
19821933 | Nov 1999 | DE |
60207576 | Jun 2006 | DE |
0068864 | Jan 1983 | EP |
0125023 | Nov 1984 | EP |
0154316 | Sep 1985 | EP |
0171496 | Feb 1986 | EP |
0173494 | Mar 1986 | EP |
0184187 | Jun 1986 | EP |
0260610 | Mar 1988 | EP |
0401384 | Dec 1990 | EP |
1334740 | Aug 2003 | EP |
1364667 | Nov 2003 | EP |
1523360 | Apr 2005 | EP |
1637181 | Mar 2006 | EP |
1257321 | Jul 2008 | EP |
2067496 | Jun 2009 | EP |
2085104 | Aug 2009 | EP |
2180459 | Apr 2010 | EP |
2361648 | Aug 2011 | EP |
2243552 | Nov 1991 | GB |
2388033 | Nov 2003 | GB |
2424837 | Oct 2006 | GB |
2465389 | May 2010 | GB |
5014835 | May 1975 | JP |
5161712 | Jun 1993 | JP |
2001-508648 | Jul 2001 | JP |
2001-512038 | Aug 2001 | JP |
2005287676 | Oct 2005 | JP |
2006-507060 | Mar 2006 | JP |
2004256 | Dec 1993 | RU |
2069584 | Nov 1996 | RU |
2131748 | Jun 1999 | RU |
2169584 | Jun 2001 | RU |
WO-1986001533 | Mar 1986 | WO |
WO-1987002671 | May 1987 | WO |
WO-1990001047 | Feb 1990 | WO |
WO-1990007861 | Jul 1990 | WO |
WO-1991003553 | Mar 1991 | WO |
WO-1991017271 | Nov 1991 | WO |
WO-1992001047 | Jan 1992 | WO |
WO-1992009690 | Jun 1992 | WO |
WO-1992015679 | Sep 1992 | WO |
WO-1992018619 | Oct 1992 | WO |
WO-1992020791 | Nov 1992 | WO |
WO-1993001288 | Jan 1993 | WO |
WO-199306213 | Apr 1993 | WO |
WO-1993013819 | Jul 1993 | WO |
WO-1993019751 | Oct 1993 | WO |
WO-1994006476 | Mar 1994 | WO |
WO-1994008609 | Apr 1994 | WO |
WO-1994009839 | May 1994 | WO |
WO-1994013342 | Jun 1994 | WO |
WO-1994026333 | Nov 1994 | WO |
WO-1997029131 | Aug 1997 | WO |
WO-1998055168 | Dec 1998 | WO |
WO-1999022789 | May 1999 | WO |
WO-1999022792 | May 1999 | WO |
WO-1999040958 | Aug 1999 | WO |
WO-1999043283 | Sep 1999 | WO |
WO-0137908 | May 2001 | WO |
WO-2001051123 | Jul 2001 | WO |
WO-2001062319 | Aug 2001 | WO |
WO-2002072636 | Sep 2002 | WO |
WO-2003039433 | May 2003 | WO |
WO-2003039633 | May 2003 | WO |
WO-2003077968 | Sep 2003 | WO |
WO-2003097133 | Nov 2003 | WO |
WO-2003099358 | Dec 2003 | WO |
WO-2004000397 | Dec 2003 | WO |
WO-2004016286 | Feb 2004 | WO |
WO-2004024211 | Mar 2004 | WO |
WO-2002012502 | Mar 2004 | WO |
WO-2004041330 | May 2004 | WO |
WO-2004047892 | Jun 2004 | WO |
WO-2004060451 | Jul 2004 | WO |
WO-2004067068 | Aug 2004 | WO |
WO-2005000206 | Jan 2005 | WO |
WO-2005002653 | Jan 2005 | WO |
WO-2005046765 | May 2005 | WO |
WO-2005079889 | Sep 2005 | WO |
WO-2005090836 | Sep 2005 | WO |
WO-2005097238 | Oct 2005 | WO |
WO-2005113039 | Dec 2005 | WO |
WO-2005115508 | Dec 2005 | WO |
WO-2005115509 | Dec 2005 | WO |
WO-2005115510 | Dec 2005 | WO |
WO-2005115511 | Dec 2005 | WO |
WO-2005115512 | Dec 2005 | WO |
WO-2005115513 | Dec 2005 | WO |
WO-2005115516 | Dec 2005 | WO |
WO-2006000785 | Jan 2006 | WO |
WO-2006057636 | Jun 2006 | WO |
WO-2006058061 | Jun 2006 | WO |
WO-2006063015 | Jun 2006 | WO |
WO-2006083876 | Aug 2006 | WO |
WO-200756231 | May 2007 | WO |
WO-2007126851 | Nov 2007 | WO |
WO-2008005315 | Jan 2008 | WO |
WO-200864092 | May 2008 | WO |
WO-200891838 | Jul 2008 | WO |
WO-2009040603 | Apr 2009 | WO |
WO-2009140251 | Nov 2009 | WO |
WO-2009155277 | Dec 2009 | WO |
WO-2010029054 | Mar 2010 | WO |
WO-201046319 | Apr 2010 | WO |
WO-201056712 | May 2010 | WO |
WO-2010055608 | May 2010 | WO |
2010066592 | Jun 2010 | WO |
WO-2010127146 | Nov 2010 | WO |
WO-2011014514 | Feb 2011 | WO |
WO-2011014704 | Feb 2011 | WO |
WO-2011075524 | Jun 2011 | WO |
WO-2011133823 | Oct 2011 | WO |
WO-2012101629 | Aug 2012 | WO |
WO-2012129174 | Sep 2012 | WO |
WO-2012135524 | Oct 2012 | WO |
Entry |
---|
Notice of Reasons for Rejection for Japanese Patent Application No. 2013-550668 dated Feb. 9, 2016 (English translation). |
English Translation of Official Action by Russian Patent Office in Russian Patent Application No. 2013139378 dated Feb. 17, 2016. |
Communication pursuant to Article 94(3) EPC by European Patent Office for European Patent Application No. 14161292.9 dated Mar. 17, 2016. |
English Translation of Office Action for Ukrainian Patent Application No. 2013 10367 issued by Ukrainian Patent Office dated May 18, 2016. |
Office Action for Chilean Patent Application 2013002111 by Chilean Patent Authority dated Jan. 16, 2017. |
English Translation of Office Action for Ukraine patent application a201310367 by Ukrainian Patent Authority dated Nov. 16, 2016. |
Office Action for Colombian patent application No. 16008364 by Colombian Patent Authority dated Mar. 15, 2017. |
English Translation of Office Action for Japan patent application No. 2013-550668 by Japanese Patent Authority dated Dec. 20, 2016. |
First Examination Report for New Zealand Application No. 722287 by the Intellectual Property Office of New Zealand dated Aug. 5, 2016. |
Resolution No. 42641 of the Colombian Patent Office regarding Colombian patent application No. 13198257 dated Jun. 27, 2016. |
Correspondence from Dept. of Health & Human Services, Food and Drug Administration, to Robert Shaw/Owen Mumford, Inc. regarding Section 501(k) notification to market device, dated Mar. 6, 2000. |
Owen Mumford drawing/schematic of the Abbott-Plunger AUTOject Mini, dated Mar. 25, 2002, Drawing No. P02 207. |
Owen Mumford drawing/schematic of the Plunger-Miniject dated Mar. 30, 1993, Drawing No. P93.022. |
Owen Mumford drawing/schematic of the Plunger-Miniject dated Mar. 30, 1993, Drawing No. AJ 358. |
Owen Mumford drawing/schematic A of the Plunger-Miniject dated Sep. 5, 1997, Drawing No. AJ 654. |
Owen Mumford drawing/schematic B of the Plunger-Miniject dated Sep. 5, 1997, Drawing No. AJ 654. |
Notice of Rejection issued in Japanese Application No. 2009-518284, dated May 29, 2012. |
International Search Report issued in International Application No. PCT/US2012/022433, dated Jul. 5, 2012. |
Written Opinion issued in International Application No. PCT/US2012/022433, dated Jul. 5, 2012. |
Communication pursuant to Article 94(3) EPC issued by the European Patent Office in European Application No. 05758156.3-2320, dated Jan. 18, 2011. |
Communication of a Notice of Opposition issued in European Application No. 04822031.3-1526, dated Jan. 6, 2010. |
Communication pursuant to Article 96(2) EPC issued in European Application No. 04822031.3-1526, dated May 31, 2007. |
Communication under Rule 112 EPC issued in European Application No. 04822031.3, dated Mar. 13, 2007. |
International Search Report issued in International Application No. PCT/GB2005/002487, dated Aug. 19, 2005. |
Written Opinion issued in International Application No. PCT/GB2005/002487, dated Dec. 23, 2006. |
International Preliminary Report on Patentability issued in International Application No. PCT/GB2005/002487, dated Sep. 7, 2006. |
International Search Report issued in International Application No. PCT/US2011/033504, dated Jul. 8, 2011. |
Written Opinion issued in International Application No. PCT/US2011/033504, dated Jul. 8, 2011. |
International Search Report issued in International Application No. PCT/US2007/015095, dated Sep. 11, 2008. |
Written Opinion issued in International Application No. PCT/US2007/015095, dated Sep. 11, 2008. |
International Preliminary Report on Patentability issued in International Application No. PCT/US2007/015095, dated Jun. 19, 2009. |
International Search Report issued in International Application No. PCT/US2010/033012, dated Jul. 2, 2010. |
Written Opinion issued in International Application No. PCT/US2010/033012, dated Jul. 2, 2010. |
International Search Report issued in International Application No. PCT/US2010/060496, dated Feb. 16, 2011. |
Written Opinion issued in International Application No. PCT/US2010/060496, dated Feb. 16, 2011. |
International Search Report issued in International Application No. PCT/US2004/013278, dated May 30, 2005. |
Written Opinion issued in International Application No. PCT/US2004/013278, dated Oct. 29, 2006. |
International Preliminary Report on Patentability issued in International Application No. PCT/US2004/013278, dated Nov. 1, 2006. |
Office Action issued in Russian Application No. 2006145501/14(049694), dated May 21, 2009. |
Decision on Grant issued in Russian Application No. 2006145501/14(049694), dated Nov. 2, 2009. |
Decision on Grant issued in Russian Application No. 2009102986/14(003862), dated Jun. 30, 2011. |
Notice of Reasons for Rejection issued in Japanese Application No. 2007-517459, dated Aug. 24, 2010. |
Notice of Reasons for Rejection issued in Japanese Application No. 2007-517459, dated Mar. 8, 2011. |
Office Action issued in Mexican Application No. PA/a/2006/015056, dated Jul. 28, 2010. |
Office Action issued in Mexican Application No. PA/a/2006/015056, dated Apr. 1, 2011. |
Reexamination Decision issued in Chinese Application No. 200580020958.6, dated Jun. 13, 2011. |
Notification of Reexamination issued in Chinese Application No. 200580020958.6, dated Aug. 17, 2010. |
Rejection Decision issued in Chinese Application No. 200580020958.6, dated Jun. 5, 2009. |
Office Action issued in Chinese Application No. 200580020958.6, dated Sep. 5, 2008. |
Office Action issued in Australian Application No. 2005256832, dated Apr. 18, 2011. |
Office Action issued in Australian Application No. 2005256832, dated Feb. 22, 2010. |
Examination Report issued in New Zealand Application No. 552340, dated Apr. 27, 2009. |
BD Preventis, Shielding System for Prefilled Syringes, http://www.bd.com/pharmaceuticals/products/safety-engineered.asp, last accessed Aug. 26, 2010. |
“Abbott Receives FDA Approval for New Humira Delivery Device,” Press Release, dated Jun. 26, 2006 (color). |
Notification of Provisional Rejection issued in Korean Application No. 10-2006-7026814, dated Jul. 19, 2011. |
Office Action issued in Canadian Application No. 2,571,571, dated Oct. 24, 2011. |
Office Action issued in Chinese Application No. 201010576413.6, dated Nov. 2, 2011. |
International Preliminary Report on Patentability issued in International Application No. PCT/US2010/033012, dated Nov. 1, 2011. |
Decision of Final Rejection issued in Japanese Application No. 2007-517459, dated Jan. 10, 2012. |
Nov. 10, 1999 correspondence from Dept. of Health & Human Services, Food and Drug Administration to Robert Shaw/Owen Mumford regarding Section 501 (k) notification intent to market device. |
Summons to Attend Oral Proceedings pursuant to Rule 115(1) EPC, dated Apr. 20, 2012. |
Inquiry issued by the Russia Federal Intellectual Property Institute on Russian Patent Application No. 2006145501/14(049694), dated May 21, 2009. |
Examination Report issued in Australian Application No. 2007269791, dated Jul. 30, 2012. |
Notice of Rejection issued in Japanese Application No. 2011-196424, dated Jan. 29, 2013. |
Invitation to Pay Additional Fees issued in International Application No. PCT/US2012/034683, dated Nov. 7, 2012. |
Examination Report issued in New Zealand Application No. 595605, dated Apr. 12, 2013. |
Office Action issued in Chinese Application No. 2010105764136, dated Jul. 31, 2012. |
International Search Report and Written Opinion issued in International Application No. PCT/US2012/029682, dated Jul. 27, 2012. |
International Search Report and Written Opinion issued in International Application No. PCT/US2012/022432, dated Apr. 18, 2012. |
Alexander et al., “Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome,” Urology 52:744 (1998). |
Gurevicius et al., “Contribution of nitric oxide to coronary vasodilation during hypercapnic acidosis,” Amer. J. Physiol.—Heart and Circulatory Physiology, vol. 268, pp. 37-42 (1995). |
Arend et al., “Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis,” Arthritis & Rheumatism 38:151-160 (1995). |
Sewell et al., “DAB IL-2 fusion toxin in refractory rheumatoid arthritis,” Arthritis & Rheumatism, vol. 36, 1223 (1993). |
Arthritis & Rheumatism, vol. 38, S185 (1995). |
Arthritis & Rheumatism, vol. 39, No. 9 (supplement), S120 (1996). |
Asakawa et al., “Effects of cernitin pollen-extract on inflammatory cytokines in sex-hormone-induced nonbacterial prostatitis rates,” Hinyokika Kiyo 47:459 (2001). |
Ausubel, F.M. et al. (eds), Current Protocols in Molecular Biology, Greene Publishing Associates (1989). |
Barbas et al., “Assembly of combinatorial antibody libraries on phage surfaces: The gene III site,” Proc. Natl. Acad. Sci. USA 88: 7978-7982 (1991). |
Beidler et al., “Cloning and high level expression of a chimeric antibody with specificity for human carcinoembrynic antigen,” J. Immunol. 141: 4056-4060 (1988). |
Better et al., “Escherichia coli secretion of an active chimeric antibody fragment,” Science 240: 1041-1043 (1988). |
Bird et al., “Single-chain antigen-binding proteins,” Science 242: 423-426 (1988). |
Boss et al., “Genetically engineered antibodies,” Immunology Today 6: 12-13 (1985). |
Braun et al., “Low secretion of tumor necrosis factor α, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis,” Arthritis Rheum. 42(10): 2039 (1999). |
Brisby et al., “Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica,” Eur. Spine J. 11: 62 (2002). |
Canfield et al., “The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the Cg2 domain and is modulated by the hinge region,” J. Exp. Med. 173: 1483-1491 (1991). |
Clackson et al., “Making antibody fragments using phage display libraries,” Nature 352: 624-628 (1991). |
Cox et al., “A Directory of Human Germ-line V78 Segments Reveals a Strong Bias in their Usage,” Eur. J. Immunol. 24: 827-836 (1994). |
Davis et al., “Structure of human tumor necrosis factor α derived from recombinant DNA,” Biochemistry 26: 1322-1326 (1987). |
Duffy et al., “Effect of nimesulide on Cox-1 and Cox-2 expression and related prostanoid formation in patients with acute knee inflammation,” ACR 66th Annual Scientific Meeting, abstract (2002). |
Eisermann et al., “Tumor necrosis factor in peritoneal fluid of women undergoing laparoscopic surgery,” Fertil. Steril. 50:573 (1988). |
Elliot et al., “Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α versus placebo in rheumatoid arthritis,” Lancet 344: 1105-1110 (1994). |
Elliot et al., “Repeated therapy with monoclonal antibody to tumour necrosis factor α in patients with rheumatoid arthritis,” Lancet 344: 1125-1127 (1994). |
Fava et al., “Critical role of peripheral blood phagocytes and the involvement of complement in tumour necrosis factor enhancement of passive collagen-arthritis,” Clin. Exp. Immunol. 94:261-266 (1993). |
Francis, “Protein modification and fusion proteins,” Focus on Growth Factors 3: 4-10 (1992). |
Fredriksson et al., “Severe psoriasis—oral therapy with a new retinoid,” Dermatologica 157: 238 (1978). |
Fuchs et al., “Targeting recombinant antibodies to the surface of Escherichia coli,” Bio/Technology 9: 1370-1372 (1991). |
Garrard et al., “FAB assembly and enrichment in a monovalent phage display system,” Bio/Technology 9: 1373-1377 (1991). |
Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). |
Gram et al., “In vitro selection and affinity maturation of antibodies from a naïve combinatorial immunoglobulin library,” Proc. Natl. Acad. Sci. US 89: 3576-3580 (1992). |
Greaves et al., “Treatment of psoriasis,” N. Eng. J. Med. 332: 581 (1995). |
Griffiths et al., “Human anti-self antibodies with high specificity from phage display libraries,” EMBO J 12: 725-734 (1993). |
Grom et al., “Patterns of expression of tumor necrosis factor α, tumor necrosis factor β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy,” Arthritis Rheum. 39: 1703 (1996). |
Halme, “Release of tumor necrosis factor-α by human peritoneal macrophages in vivo and in vitro,” Am. J. Obstet. Gynecol. 161:1718 (1989). |
Harris et al., “Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostrate,” Prostate 44:25 (2000). |
Hawkins et al., “Selection of phage antibodies by binding affinity,” J. Mol. Biol. 226: 889-896 (1992). |
Hay et al., “Bactriophage cloning and Escherichia coli expression of a human IgM Fab,” Hum. Antibod. Hybridomas 3: 81-85 (1992). |
Hollinger et al., “Diabodies: small bivalent and bispecific antibody fragments,” Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993). |
Hoogenboom et al., “Multi-subunit proteins on the surface of filamentous phage,” Nuc. Acid. Res. 19: 4133-4137 (1991). |
Huse, W.D. et al. “Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda” Science, 246:1275-81 (1989). |
Huskisson, “Measurement of pain,” Lancet 304: 1127-1131 (1974). |
Huston et al., “Protein engineering of antibody binding sites,” Proc. Natl. Acad. Sci. USA 85: 5879-5883 (1988). |
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature 321: 552-525 (1986). |
Jones et al., “Structure of tumour necrosis factor,” Nature 338: 225-228 (1989). |
Johnsson et al., “Immobilization of proteins to a carboxymethyldextran-modified bold surface for biospecific interaction analysis in surface plasmon resonance sensors,” Anal. Biochem. 198: 268 (1991). |
Johnsson et al., “Comparison of methods for immobilization to carboxymethyl dextran sensor surfaces by analysis of the specific activity of monoclonal antibodies,” J. Mol. Recognit. 8: 125 (1995). |
Jonsson et al., “Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology,” Biotechniques 11: 620-627 (1991). |
Jonsson et al., “Introducing a biosensor based technology for real-time biospecific interaction analysis,” Ann. Biol. Clin. 51: 19 (1992). |
Jorgensen et al., “Pain assessment of subcutaneous injections,” Annals of Pharmacotherapy 30: 729-732 (1996). |
Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 (1991). |
Kaijtzel et al., “Polymorphism within the tumor necrosis factor α promoter region in patients with ankylosing spodylitis,” Hum. Immunol. 60: 140 (1999). |
Kaufman et al., “Amplification and expression of sequences contransfected with a modular dihydrofolate reducatase complementary DNA gene,” Mol. Biol. 159: 601-621 (1982). |
Koski et al., “Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sjogren's syndrome,” Clin. Exp. Rheumatol. 19: 131 (2001). |
Liu et al., “Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity,” J. Immunol. 139: 3521-3526 (1987). |
Liu et al., “Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells,” J. Immunol. 84: 3439-3443 (1987). |
Lund et al., “Human FcRI and FcRII interact with distinct but overlapping sites on human IgG,” J. of Immunol. 147: 2657-2662 (1991). |
MacDonald et al., “Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine,” Clin. Exp. Immunol. 81:301 (1990). |
Mackiewicz et al., “Dual effects of caspase-1, interleukin-1β, tumour necrosis factor-α and nerve growth factor receptor in inflammatory myopathies,” Clin. Exp. Rheumatol. 21: 41 (2003). |
Mangge et al., “Serum cytokines in juvenile rheumatoid arthritis,” Arthritis Rheum. 8: 211 (1995). |
Marks et al., “Assessment of disease progress in psoriasis,” Arch. Dermatol. 125: 235 (1989). |
McCafferty et al., “Phase antibodies,” Nature 348: 552-554 (1990). |
Moeller et al., “Monoclonal antibodies to human tumor necrosis factor α,” Cytokine 2: 162169 (1990). |
Mori et al., “Peritoneal fluid interleukin-1β and tumor necrosis in patients with benign gynecologic disease,” Am. J. Reprod. Immunol. 26:62 (1991). |
Morrison, “Transfectomas provide novel chimeric antibodies,” Science 229: 1202-1207 (1985). |
Murota et al., “Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced sclerodermic skin fibroblasts,” Arthritis Rheum. 48: 1117 (2003). |
Nadler et al., “IL-1β and TNF-α in prostratic secretions are indicators in the evaluation of men with chronic prostatitis,” J. Urol. 164:214 (2000). |
Nishimura et al., “Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocyte leukemia antigen,” Cancer Res. 47: 999-1005 (1987). |
Oh H. et al., “The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes,” Invest. Ophthalmol. Vis. Sci 40:1891 (1999). |
Oi et al., “Chimeric antibodies,” BioTechniques 4:214 (1986). |
Orhan et al., “Seminal plasma cytokine levels in the diagnosis of chronic pelvic pain syndrome,” Int. J. Urol. 8:495 (2001). |
Overton et al., “Peritoneal fluid cytokines and the relationship with endometriosis and pain,” Hum. Reprod. 11:380 (1996). |
Ozaktay et al., “Dorsal root sensitivity to interleukin-1 beta, interleukin-6 and tumor necrosis factor in rats,” Eur. Spine J. 11: 467 (2002). |
Partsch et al., “T cell derived cytokines in psoriatic arthritis synovial fluids,” Ann. Rheum. Dis. 57: 691 (1998). |
Pennica et al., “Human tumour necrosis factor,” Nature 312: 724-729 (1984). |
Poljak et al., “Production and structure of diabodies,” Structure 2: 1121-1123 (1994). |
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,” Proc. Natl. Acad. Sci. USA 86: 10029-10033 (1989). |
Rankin et al., “The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody in rheumatoid arthritis,” Br. J. Rheumatol. 34: 334-342 (1995). |
Reuss-Borst et al., “Sweet's syndrome associated with myelodysplasia,” Br. J. Haematol. 84: 356 (1993). |
Ritchlin et al., “Patterns of cytokine production in psoriatic synovium,” J. Rheumatol. 25: 1544 (1998). |
Sambrook, Fritsch and Maniatis (eds), Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y. (1989). |
Schwartzman et al., “Does route of administration affect the outcome of TNF antagonist theraphy?” Arthritis Research & Therapy 6(Suppl 2): S19-S23 (2004). |
Shaw et al., “Mouse/human chimeric antibodies to a tumor-associated antigen,” J. Natl. Cancer Inst. 80: 1553-1559 (1988). |
Shvidel et al., “Cytokine release by activated T-cells in large granular lymphocytic leukemia associated with autoimmune disorders,” Hematol. J. 3:32 (2002). |
Sklavounou et al., “TNF-α and apoptosis-regulating proteins in oral lichen planus,” J. Oral. Pathol. Med. 29: 370 (2000). |
Studnicka-Benke et al., “Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus,” Br. J. Rheumatol. 35:1067 (1996). |
Sun et al., “Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor,” J. Clin. Invest. 81:1328 (1988). |
Sun et al., “Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A,” Proc. Natl. Acad. Sci. USA 84: 214-218 (1987). |
Takematsu et al., “Absence of tumor necrosis factor-α in suction blister fluids and stratum corneum from patients with psoriasis,” Arch. Dermatol. Res. 281: 398 (1989). |
Taketani et al., “Comparison of cytokine levels and embryo toxicity in peritoneal fluid in infertile women with untreated or treated endometriosis,” Am. J. Obstet. Gynecol. 167:265 (1992). |
Taurog et al., The Spondylarthritides, Oxford: Oxford University Press (1998). |
Taylor et al., “A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins,” Nucl. Acids Res. 20: 6287 (1992). |
Tomlinson, Ian M. et al., “The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops,” J. Mol. Biol., vol. 227:776-798 (1992). |
Tracy et al., “Shock and tissue injury induced by recombinant human cachectin,” Science 234:470 (1986). |
Tsutsumimoto et al., “TNF-α and IL-β suppress N-Cadherin expression in MC3T3-E1 cells,” J. Bone Miner. Res. 14: 1751 (1999). |
Tutuncu et al., “Anti-TNF therapy for other inflammatory conditions,” Clin. Exp. Rheumatol. 20(6 Suppl 28): S146 (2002). |
Urlaub et al., “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity,” Proc. Natl. Acad. Sci. USA 77: 4216-4220 (1980). |
van Dulleman et al., “Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody,” Gastroenterology 109:129 (1995). |
Venn et al., “Elevated synovial fluid levels of interleukin-6 and tumor necrosis factor associated with early experimental canine osteoarthritis,” Arthritis and Rheum. 36: 819 (1993). |
Verhoeyen et al., “Reshaping human antibodies,” Science 239: 1534 (1988). |
Verjans et al., “Restriction fragment length polymorphism of the tumor necrosis factor region in patients with ankylosing spodylitis,” Arthritis Rheum. 34: 486 (1991). |
Verjans et al., “Polymorphism of tumour necrosis factor-alpha at position—308 in relation to ankylosing spondylitis,” Clin. Exp. Immunol. 97: 45 (1994). |
Victor et al., “TNF-alpha and apoptosis,” J. Drugs Dermatol. 1: 264 (2002). |
Wakefield et al., “The role of cytokines in the pathogenesis of inflammatory eye disease,” Cytokine 4:1 (1992). |
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli,” Nature 341: 544-546 (1989). |
Wood et al., “The synthesis and in vivo assembly of functional antibodies in yeast,” Nature 314: 446-449 (1985). |
Woon et al., “Kinetics of cytokine production in experimental autoimmune anterior uveitis,” Curr. Eye Res. 17: 955 (1998). |
Zeidler et al., “Undifferentiated spodyloarthropathies,” Rheum. Dis. Clin. North Am. 18: 187 (1992). |
Arthritis & Rheumatism, vol. 39, No. 9, S282 (1996). |
Arthritis & Rheumatism, vol. 39, No. 9, S284 (1996). |
Arthritis & Rheumatism, vol. 39, No. 9, S296 (1996). |
Arthritis & Rheumatism, vol. 39, No. 9, S308 (1996). |
Arthritis & Rheumatism, vol. 39, No. 9, S81 (1996). |
Arthritis & Rheumatism, vol. 39, No. 9, S82 (1996). |
International Preliminary Report on Patentability issued in PCT/US2010/060496, dated Jun. 19, 2012. |
Examination Report issued in Australian Application No. 2010331936, dated Nov. 12, 2012. |
Examination Report issued in New Zealand Application No. 600069, dated Mar. 28, 2013. |
Office Action issued in Chinese Application No. 201080029621.2, dated Feb. 27, 2013. |
International Search Report issued in International Application No. PCT/US2012/029682, dated Jul. 27, 2012. |
Written Opinion issued in PCT/US2012/029682, dated Jul. 27, 2012. |
PCT International Search Report and Written Opinion dated Jun. 26, 2013 for PCT/US2013/028619. |
International Preliminary Report on Patentability on International Application No. PCT/US2012/022433 dated Jul. 30, 2013. |
Patent Examination Report by IP Australia, dated May 30, 2014. |
First Examination Report by New Zealand Intellectual Property Office dated May 26, 2014. |
European Search Report on Application No. 1416292.2, dated May 23, 2014. |
European Examination Report in Application No. 12701430.6, dated Apr. 8, 2014. |
Written Opinion of the Austrian Patent Office for Singapore Patent Application No. 201305645-2 dated Jul. 23, 2014. |
English Translation of the Office Action by the Colombian Patent Office for Colombian Patent No. 13198257 dated Nov. 21, 2014. |
English Translation of the First Office Action by the State Intellectual Property Office of PRC for Chinese Application No. 201280014851.0 dated Nov. 19, 2014. |
Office Action issued by the Dominican Patent Office for application 2013-0167 dated May 7, 2015. |
Translation of the First Office Action issued by the Mexican Institute of Industrial Property (IMPI) for application No. MX/a/2013/008611 dated Jul. 3, 2015. |
Communication pursuant to Article 94(3) EPC by European Patent Office for European application No. 12701430.6 dated Aug. 21, 2015. |
Number | Date | Country | |
---|---|---|---|
20160158450 A1 | Jun 2016 | US |
Number | Date | Country | |
---|---|---|---|
61435465 | Jan 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13357507 | Jan 2012 | US |
Child | 15047262 | US |